Zusammenfassung
Der testikuläre Keimzelltumor (KZT) repräsentiert den häufigsten bösartigen Tumor bei 20- bis 40-jährigen Männern. Die Altersverteilung unterscheidet sich von den übrigen soliden Neoplasien des Menschen insofern, als ein 1. Altersgipfel zwischen dem 25. und 35. Lebensjahr, ein 2. geringerer Gipfel mit >80. Jahren auftritt.
In den vergangenen 30–40 Jahren haben viele klinische Untersuchungen die Risikofaktoren analysiert, die in die Entwicklung und Progression der KZT involviert sind. Als wesentliche Parameter haben sich Maldescensus testis und junges Alter herauskristallisiert. Neben der onkologischen Kennzeichnung dieses urologischen Malignoms und molekularbiologischen Aspekten sind in diesem Kapitel die Diagnostik und Therapie von Seminomen und Nichtseminomen sowie der testikulären intraepithelialen Neoplasie (TIN) thematisiert. Auch die seltenen Hodentumoren wie Keimstrang-/Stroma-, Leydig- und Sertoli-Zelltumoren, Gnoadoblastom und Granulosazelltumoren sind hier kurz beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Literatur zu ▶ Abschn. 25.1
Akre O, Ekbom A, Sparen P et al. (2000) Body size and testicular cancer. J Natl Cancer Inst 92: 1093–1096
Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD (2011) Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953–2007). Int J Cancer 129 (12): 2867–74
Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617–631
Brody JP (2011) Age-specific incidence data indicate four mutations are required for human testicular cancers. PLoS One 6 (10): e25978
Brown LM, Pottern LM, Hoover RN et al. (1986) Testicular cancer in the United States: rends in incidence and mortality. Int J Epidemiol 15: 164–170
Cannon-Albright LA, Thomas A, Goldgar DE et al. (1994) Familiality of cancer in Utah. Cancer Res 54: 2378–2385
Carlesen E, Giwercman A, Keiding N et al. (1992) Evidence for decreasing quality of semen during the last 50 years. BMJ 305: 609–612
Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA (2010) International trends in the incidence of testicular cancer, 1973–2002. Cancer Epidemiol Biomarkers Pre 19 (5): 1151–9
Coupland CAC, Forman D, Chilvers CED et al. (2004) Maternal risk factors for testicular cancer: a population-based case control study (UK). Cancer Causes Control 15: 277–283
Davies TW, Palmer CR, Ruja E et al. (1996) Adolescent milk, dairy product and fruit consumption and testicular cancer. Br J Cancer 74: 657–660
Dieckmann KP, Pichlmeier U (2002) Is risk of testicular cancer related to body size? Eur Urol 2: 564–569
Dieckmann KP, Pichlmeier U (2004) Clinical epidemiology of testicular germ cell tumors. World J Urol 22: 2–14
Ganmaa D, Li XM, Wang J et al. (2002) Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. Int J Cancer 98: 262–267
Garner MJ, Birkett NJ, Johnson KC (2003) Dietary risk factors for testicular carcinoma. Int J Cancer 106: 934–941
Garner MJ, Turner MC, Ghadiriam P et al. (2005) Epidemiology of testicular cancer: an overview. Int J Cancer 116: 331–339
Giwercman A, Grindsted J, Hansen B et al. (1987) Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol 138: 1214–1216
Giwercman A, Muller J, Skakkebaek NE (1988) Cryptorchidism and testicular neoplasia. Horm Res 30: 157–163
Haughey BP, Graham S, Brasure J et al. (1989) The epidemiology of testicular cancer in upstate New York. Am J Epidemiol 130: 25–36
Heimdahl K, Olsson H, Tretli S et al. (1996) Familial testicular cancer in Norway and southern Sweden. Br J Cancer 73: 964–969
Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11
Jacobsen R, Bostofte E, Engholm G et al. (2000) Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 321: 789–792
Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, Albano A, Chen C, Starr JR, Rader DJ, Godwin AK, Reilly MP, Hakonarson H, Schwartz SM, Nathanson KL (2009) Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41 (7): 811–5
Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, Letrero R, D’Andrea K, Vaddi M, Doody DR, Weaver J, Chen C, Starr JR, Håkonarson H, Rader DJ, Godwin AK, Reilly MP, Schwartz SM, Nathanson KL (2011) A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet 20 (15): 3109–17
McKiernan JM, Goluboff ET, Liberson GL et al. (1999) Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 162: 361–367
Moller H (1997) Work in agriculture, childhood resistance, nitrate exposure, and testicular cancer risk: a case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 6: 141–144
Moller H, Jorgensen N, Fordham D (1995) Trends in incidence of testicular cancer in boys and adolescent men. Int J Cancer 61: 761–764
Moller H, Skakkebaek NE (1996) Risk of testicular cancer and cryptorchidism in relation to socioeconomic status and related factors: case – control studies in Denmark. Int J Cancer 66: 287–293
Moss AR, Osmond D, Bachetti P et al. (1986) Hormonal risk factors in testicular cancer. A case control study. Am J Epidemiol 124: 39–52
Nordsborg RB, Meliker JR, Wohlfahrt J, Melbye M, Raaschou-Nielsen O (2011) Cancer in first-degree relatives and risk of testicular cancer in Denmark. Int J Cancer 129 (10): 2485–91
Oesterlind A (1986) Diverging trends in incidence and mortality of testicular cancer in Denmark 1943–1982. Br J Cancer 53: 501–505
Parkin DM, Shanmugarathnam K, Sobin L et al. (1998) Histological groups for comparative studies. Lyon: IARC
Pearce N, Sheppard RA, Howard JK et al. (1987) Time trends and occupational differences in cancer of the testis in New Zealand. Cancer 59: 1677–1682
Pottern LM, Morris Brown L, Hoover RN et al. (1985) Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J Natl Cancer Inst 74: 377–381
Prener A, Hsieh AA, Engholm G et al. (1992) Birth order and risk of testicular cancer. Cancer Causes Control 3: 265–272
Rapley EA, Crockford GP, Teare D et al. (2000) Localisation to Xq27 of a susceptibility gene for testicular germ-cell tumors. Nat Genet 24: 197–200
Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, Morrison J, Nsengimana J, Deloukas P, UK Testicular Cancer Collaboration, Rahman N, Bishop DT, Easton DF, Stratton MR (2009) A genome-wide association study of testicular germ cell tumor. Nat Genet 41 (7): 807–10
Richiardi L, Akre O, Lambe M et al. (2004) Birth order, sidship size, and risk for germ-cell testicular cancer. Epidemiology 15: 323–329
Richiardi L, Askling J, Granath F et al. (2003) Body size at birth and adulthood and the risk for germ-cell testicular cancer. Cancer Epidemiol Biomarkers Prev 12: 669–673
Rorth M, Rajpert-De Meyts E, Andersson L et al. (2000) Carcinoma in situ in the testis. Scand J Urol Nephrol Suppl: 166–186
Rosen A, Jayram G, Drazer M, Eggener SE (2011) Global trends in testicular cancer incidence and mortality. Eur Urol 60 (2): 374–9
Shah MN, Devesa SS, Zhu K, McGlynn KA (2007) Trends in testicular germ cell tumours by ethnic group in the United States. Int J Androl 30 (4): 206–13
Sharpe RM, Skakkebaek NE (1993) Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341: 1392–1395
Sigurdson AJ, Chang S, Annegers JF et al. (1999) A case-control study of diet and testicular carcinoma. Nutr Cancer 34: 20–26
Swerdlow AJ, Higgins CD, Pike MC (1997) Risk of testicular in a cohort of boys with cryptorchidism. BMJ 314: 1507–1511
Swerdlow AJ, Huttly SR, Smith P (1989) Testis cancer: post-natal hormonal factors, sexual behaviour and fertility. Int J Cancer 43: 549–553
Swerdlow AJ, Skeet RG (1988) Occupational associations of testicular cancer in South East England. Br J Ind Med 45: 225–230
Trabert B, Sigurdson AJ, Sweeney AM, Amato RJ, Strom SS, McGlynn KA (2011) Baldness, acne and testicular germ cell tumours. Int J Androl 34 (4 Pt 2): e59–67
Troisi R, Potischman N, Roberts J et al. (2003) Associations of maternal and umbilical cord hormone concentrations with maternal gestational and neonatal factors (United States). Cancer Causes Control 14: 347–355
Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, Huddart RA, Bishop DT, Easton DF, Stratton MR, Rahman N (2010) UK Testicular Cancer Collaboration. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet 42 (7): 604–607
United Kingdom Testicular Cancer Study Group (1994) Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility and exercise. BMJ 308: 1393–1399
Wanderas EH, Grotmol T, Fosså SD et al. (1998) Maternal health and pre- and perinatal characteristics in the etiology of testicular cancer: a prospective population and register-based study on Norwegian male borns between 1967 and 1995. Cancer Causes Control 9: 475–486
Wanderas EH, Tretli S, Fosså SD (1995) Trends in incidence of testicular cancer in Norway 1955–1992. Eur Urol 31A: 2044–2048
Weir HK, Marrett LD, Kreiger N et al. (2000) Prenatal and perinatal exposures and risk of testicular germ cell cancer. Int J Cancer 87: 438–443
Westergaard T, Andersen PK, Pedersen JB et al. (1998) Testicular cancer risk and maternal parity: a population-based cohort study. Br J Cancer 77: 1180–1185
Westergaard T, Olsen JH, Frisch M et al. (1996) Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer 66: 627–631
Literatur zu ▶ Abschn. 25.2
Bhatt S, Jafri SZ, Wasserman N, Dogra VS (2011) Imaging of non-neoplastic intratesticular masses. Diagn Interv Radiol 17 (1): 52–63
Bosl GH, Goldman A, Lange PH et al. (1981) Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 2: 970–973
Dieckmann KP, Kulejewski M, Heinemann V, Loy V (2011) Testicular biopsy for early cancer detection–objectives, technique and controversies. Int J Androl 34 (4 Pt 2): e7–13
Elzinga-Tinke JE, Sirre ME, Looijenga LH, van Casteren N, Wildhagen MF, Dohle GR (2010) The predictive value of testicular ultrasound abnormalities for carcinoma in situ of the testis in men at risk for testicular cancer. Int J Androl. 2010 Aug 1;33 (4): 597–603
Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P (2007) Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol 52 (6): 1710–6
Krege S, Albers P, Heidenreich A (2011) The role of tumour markers in diagnosis and management of testicular germ cell tumours. Urologe A 50 (3): 313–21
Moul JW, Paulson DF, Dodge RK et al. (1990) Delay in diagnostic and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990: 520–523
Nikzas S, Champion AE, Fox M (1990) Germ cell tumors of testis: prognostic factors and results. Eur Urol 18: 242
Oliver RTD (1985) Factors contributing to delay in diagnosis of testicular tumors. Brit Med J 290: 356
Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European germ cell cancer consensus group (EGCCCG). Ann Oncol 15: 1377–1399
Tan IB, Ang KK, Ching BC, Mohan C, Toh CK, Tan MH (2010) Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review. Cancer 116 (19): 4520–32
Valentino M, Bertolotto M, Derchi L, Bertaccini A, Pavlica P, Martorana G, Barozzi L (2011) Role of contrast enhanced ultrasound in acute scrotal diseases. Eur Radiol 21 (9): 1831–40
Literatur zu ▶ Abschn. 25.3
Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763–1767
Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090
Antonsson B, Martinou JC (2000) The Bcl-2 protein family. Exp Cell Res 256: 50–57
Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 20: 1864–1873
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295–1302
Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J.Cancer 73: 592–599
Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, Stoter G (1999) Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 81: 620–628
Cairns J (2002) Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc Natl Acad Sci USA 99: 10567–10570
Chaganti RS, Houldsworth J (2000) Genetics and biology of adult human male germ cell tumors. Cancer Res 60: 1475–1482
Chresta CM, Masters JR, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56: 1834–1841
de Jong J, Stoop H, Dohle GR, Bangma CH, Kliffen M, van Esser JW, van den BM, Kros JM, Oosterhuis JW, Looijenga LH (2005) Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol 206: 242–249
Devouassoux-Shisheboran M, Mauduit C, Bouvier R, Berger F, Bouras M, Droz JP, Benahmed M (2001) Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours. Mol Hum Reprod 7: 1099–1105
Faulkner SW, Friedlander ML (2000) Microsatellite instability in germ cell tumors of the testis and ovary. Gynecol Oncol 79: 38–43
Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB (1998) Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 77: 741–746
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869–1883
Gondos B (1993) Ultrastructure of develo** and malignant germ cells. Eur Urol 23: 68–74
Gondos B, Migliozzi JA (1987) Intratubular germ cell neoplasia. Semin Diagn Pathol. 4: 292–303
Gueler B, Sonne SB, Zimmer J, Hilscher B, Hilscher W, Graem N, Rajpert-De Meyts E, Vogt PH (2012) AZFa protein DDX3Y is differentially expressed in human male germ cells during development and in testicular tumours: new evidence for phenotypic plasticity of germ cells. Hum Reprod
Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE, van der KH (2011) p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One 6: e19198
Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151–157
Hardman RA, Afshari CA, Barrett JC (2001) Involvement of mammalian MLH1 in the apoptotic response to peroxide-induced oxidative stress. Cancer Res 61: 1392–1397
Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH (2003) Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 83: 1489–1495
Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, Oechsle K, Steyerberg EW, Hartmann JT, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment resistant germ cell tumors. J Clin Oncol 1, 27: 2129–2136
Houldsworth J, **ao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16: 2345–2349
Huddart RA, Wooster R, Horwich A, Cooper CS (1995) Microsatellite instability in human testicular germ cell tumours. Br J Cancer 72: 642–645
Jacob S, Aguado M, Fallik D, Praz F (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61: 6555–6562
Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH (2002) Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20: 1551–1561
Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y, Fukushima S, Takeuchi Y (2006) Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother Pharmacol 57: 84–90
Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T (2008) Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 62: 577–584
Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J.Cancer 70: 551–555
Koberle B, Masters JR, Hartley JA, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273–276
Koberle B, Roginskaya V, Zima KS, Masters JR, Wood RD (2008) Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog 47: 580–586
Konig J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377–394
Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den BA, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120: 3594–3605
Lage H, Dietel M (1999) Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 125: 156–165
Looijenga LH (2011) Spermatocytic seminoma: toward further understanding of pathogenesis. J Pathol 224: 431–433
Looijenga LH, Oosterhuis JW (1999) Pathogenesis of testicular germ cell tumours. Rev Reprod. 4: 90–100
Lothe RA, Peltomaki P, Tommerup N, Fosså SD, Stenwig AE, Borresen AL, Nesland JM (1995) Molecular genetic changes in human male germ cell tumors. Lab Invest 73: 606–614
Lutzker SG, Levine AJ (1996) A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 2: 804–810
Lutzker SG, Mathew R, Taller DR (2001) A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 20: 2982–2986
Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H (1996) Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A: 1248–1253
Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH (2002) Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62: 2758–2760
Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767–773
Mostert MC, Verkerk AJ, van de PM, Heighway J, Marynen P, Rosenberg C, van Kessel AG, van Echten J, de Jong B, Oosterhuis JW, Looijenga LH (1998) Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 16: 2617–2627
Mostofi FK (1973) Proceedings: Testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 32: 1186–1201
Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C, Mayer F (2006) Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol. 29: 471–479
Oosterhuis JW, Looijenga LH (2005) Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5: 210–222
Oosterhuis JW, Looijenga LH, van Echten J, de Jong B (1997) Chromosomal constitution and developmental potential of human germ cell tumors and teratomas. Cancer Genet Cytogenet 95: 96–102
Ottesen AM, Skakkebaek NE, Lundsteen C, Leffers H, Larsen J, Rajpert-De Meyts E (2003) High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. Genes Chromosomes Cancer 38: 117–125
Rajpert-De Meyts E, Bartkova J, Samson M, Hoei-Hansen CE, Frydelund-Larsen L, Bartek J, Skakkebaek NE (2003) The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 111: 267–278
Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331–344
Rosenberg C, van Gurp RJ, Geelen E, Oosterhuis JW, Looijenga LH (2000) Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene 19: 5858–5862
Sandberg AA, Meloni AM, Suijkerbuijk RF (1996) Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. J Urol 155: 1531–1556
Savage P, Stebbing J, Bower M, Crook T (2009) Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 6: 43–52
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1: 578–582
Skakkebaek NE (1972) Possible carcinoma-in-situ of the testis. Lancet 2: 516–517
Spierings DC, de Vries EG, Vellenga E, de Jong S (2003a) Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10: 808–822
Spierings DC, de Vries EG, Vellenga E, de Jong S (2003b) The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli. J Pathol 200: 137–148
Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D (1991) Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci U.S A 88: 6662–6666
Ulbright TM (1993) Germ cell neoplasms of the testis. Am J.Surg Pathol 17: 1075–1091
Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Pizarro J, Berlin A, Ittmann M, Koh MS, Leach FS (2004) Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther 3: 977–982
Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169–1181
Wylie C (1999) Germ cells. Cell 96: 165–174
Literatur zu ▶ Abschn. 25.4
Brydoy M, Fossa SD, Klepp O et al. (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97: 1580–1588
Canil CM, Tannock IF (2002) Doctor‘s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29: 286–293
DeSantis M, Bokemeyer C Becherer A et al. (2001) Predictive impact of 2-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740–3744
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51: 175–185
Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14: 3126–3132
Elzinga-Tinke JE, Sirre ME, Looijenga LH, van Casteren N, Wildhagen MF, Dohle GR (2010) The predictive value of testicular ultrasound abnormalities for carcinoma in situ of the testis in men at risk for testicular cancer. Int J Androl 33: 597–603
Hamm B (1997) Differential diagnosis of scrotal masses by ultrasound. Eur Radiol 7: 668–679
Hansen J, Jurik AG (2009) Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. Acta Radiol 50: 1064–1070
Holm M, Hoei-Hansen CE, Rajpert-de Meyts E et al. (2003) Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle. J Urol 170: 1163–1167
Huddart R, O`Doherty M, Padhani A et al. (2008) A prospective study of 18FDG PET in the prediction of relapse in patients with stage I (CSI) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. ASCO, abstract 4520
International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: A prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603
Jacobson GK, Norgaard Pedersen B (1986) Placental alkaline phosphatase in testicular germ cell tumours and in carcinoma-in-situ of the testis. In: Jones WG, Milford WA, Anderson CK (eds) Germ cell tumours II. Pergamon, Oxford, p 157
Kim C, McGlynn KA, McCorkle R et al. (2010) Fertility among testicular cancer survivors: a case-control study in the US. J Cancer Surviv 4: 266–273
Kliesch S (2003) Fertilität bei Patienten mit Hodentumorerkrankungen. Onkologe 9: 955–961
Krege S, Beyer J, Souchon R et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 53: 478–496
Krug B, Heidenreich A, Dietlein M et al. (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren. Fortschr Röntgenstr 171: 87–94
Lassen U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402
May M, Helke C, Nitzke T et al. (2004) Diagnostic value of tumour marker regression models in stage I marker-positive testicular cancer. Urol Int 73: 329–336
Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534–2541
Meyer CA, Conces DJ (2002) Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am 12: 717–738
Nagler-Reus M, Guhl L, Volz C, Wuerstlin S, Arlart IP (1995) Magnetic resonance tomography of the scrotum. Experiences with 129 patients. Radiologe 8: 494–503
Nicolai N, Miceli R, Artusi R et al. (2004) A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171: 172–176
Salesi N, Di Cocco B, Alghisi F et al. (2002) Testis cancer markers. Clinical use. Minerva Med 93: 365–369
Schmidt KL, Larsen E, Bangsboll S et al. (2004) Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples. Hum Reprod 19: 2806–2810
Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399
Sobin LH, Gospodarowicz MK, Wittekind C (eds.) (2009) UICC: TNM classification of malignant tumours, 7th edn. John Wiley & Sons, New York
Sobin LH, Wittekind Ch (eds.) (2002) UICC: TNM classification of malignant tumours. Sixth edition. Wiley-Liss, Inc., New York
Stensheim H, Cvancarova M, Moller B, Fossa D (2011) Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 129: 1225–1236
TRISST (MRC TE24) Trial of imaging and schedule in seminoma testis. [http://www.ctu.mrc.ac.uk/svtudies/TE24.asp]
White PM, Adamson DJA, Howard GCW et al. (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54: 207–211
Literatur zu ▶ Abschn. 25.5
Aki FT, Bilen CY, Tekin MI, Ozen H (2000) Is scrotal violation per se a risk factor for local relapse and metastases in stage I nonseminomatous testicular cancer? Urology 56: 459–462
Al-Assiri M, Kevin Z, Binsaleh S, Chan PT (2005) Surgical approach of giant testicular cancer. Case report and literature review. Can J Urol 12: 2557–9
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP (2011) EAU Guidelines on Testicular Cancer: 2011 update. Eur Urol 60: 304–319
Albers P, Dieckmann K-P (1998) Hodentumoren: Diagnostik und Therapie des Primärtumors. Onkologe 4: 487–493
Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD (2011) Risk of metachronous contralateral testicular germ cell tumors: A population-based study of 7,102 Norwegian patients (1953–2007). Int J Cancer 129: 2867–2874
Angulo JC, González J, Rodríguez N, Hernández E, Núñez C, Rodríguez-Barbero JM, Santana A, López JI (2009) Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). J Urol 182: 2303–2310
Ashdown DA, Bodiwala D, Liu S (2004) Is high cord radical orchidectomy always necessary for testicular cancer? Ann R Coll Surg Engl 86: 289–291
Azzopardi JG, Mostofi FK, Theiss EA (1961) Lesions of the testes observed in certain patients with widespread choriocarcinoma and related tumors. The significance and genesis of hematoxylin-staining bodies in the human testis. Amer J Pathol 38: 207–225
Bell D, Morash C, Dranitsaris G, Izawa J, Short T, Klotz LH, Fleshner N (2006) Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 13 Suppl 3: 30–6
Bochner BH, Lerner SP, Kawachi M, Williams RD, Scardino PT, Skinner DG (1995) Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology 46: 408–411
Bodiwala D, Summerton DJ, Terry TR (2007) Testicular prostheses: development and modern usage. Ann R Coll Surg Engl 89: 349–353
Boileau MA, Steers WD (1984) Testis tumors: the clinical significance of the tumor-contaminated scrotum. J Urol 132: 51–54
Bolten M, Weissbach L, Kaden R (2005) Kryokonservierte humane Spermadepots. Brauchbarkeit nach jahrzehntelanger Lagerung. Urologe A 44: 904–908
Boy D, Carl P (2002) Akzeptanz von Silikonhodenprothesen im Langzeitverlauf. Urologe A 41: 462–469
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O; for the Norwegian Urology Cancer Group III study group (2010) Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. Eur Urol 58: 134–141
Capelouto CC, Clark PE, Ransil BJ, Loughlin KR (1995) A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 153: 981–985
Carver BS, Heidenreich A, Sogani P (2010) Radical orchiectomy and testis sparing procedures for the management of germ cell tumors. In Cancer of the testis., Laguna M P, Albers P, Bokemeyer C, Richie JP (eds) pp 125–130. London: Springer
Chapple A, McPherson A (2004) The decision to have a prosthesis: A qualitative study of men with testicular cancer. Psychooncology 13: 654–664
Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657–660
Colpi GM, Carmignani L, Nerva F, Guido P, Gadda F, Castiglioni F (2005) Testicular-sparing microsurgery for suspected testicular masses. BJU Int 96: 67–69
Dieckmann KP (2007) Diagnostic Delay in Testicular Cancer: An Analytic Chimaera or a Worthy Goal? Eur Urol 52: 1566–1568
Dieckmann KP, Heinemann V, Frey U, Pichlmeier U (2005) How Harmful is Contralateral Testicular Biopsy?-An Analysis of Serial Imaging Studies and a Prospective Evaluation of Surgical Complications. Eur Urol 48: 662–672
Dieckmann KP, Kulejewski M, Heinemann V, Loy V (2011) Testicular biopsy for early cancer detection - objectives, technique and controversies. Int J Androl 34: e7–e13
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) Diagnosis of Contralateral Testicular Intraepithelial Neoplasia (TIN) in Patients with Testicular Germ Cell Cancer: Systematic two-Site biopsies are more sensitive than a single Random Biopsy. Eur Urol 51: 175–185
Dieckmann KP, Loy V (1993) Seminoma testis after testis sparing excision of testicular teratoma. Brit J Urol 71: 612–613
Dieckmann KP, Loy V (2003) False-Negative Biopsies for the Diagnosis of Testicular Intraepithelial Neoplasia (TIN) - An Update. Eur Urol 43: 516–521
Elert A, Olbert P, Hegele A, Barth P, Hofmann R, Heidenreich A (2002) Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol 41: 290–3
Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299: 672–684.
Fosså SD, Aass N, Heilo A, Daugaard G, Skakkebaek NE, Stenwig AE, Nesland JM, Looijenga LH, Oosterhuis JW (2003) Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol 14: 1412–1418
Fosså SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, Travis LB (2005) Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 97: 1056–1066
Geldart TR, Simmonds PD, Mead GM (2002) Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 90: 451–455
Giannarini G, Dieckmann KP, Albers P, Heidenreich A, Pizzocaro G (2010) Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. Eur Urol 57: 780–790
Goldstein M, Waterhouse K (1983) When to use the Chevassu maneuver during exploration of intrascrotal masses. J Urol 130: 1199–1200
Harding M, Paul J, Kaye SB (1995) Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours? Br J Urol 76: 491–494
Harland SJ, Cook PA, Fosså SD, Horwich A, Mead GM, Parkinson MC, Roberts JT, Stenning SP (1998) Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group. J Urol 160: 1353–1357
Hartmann JT, Fosså SD, Nichols CR, Droz JP, Horwich A, Gerl A, Beyer J, Pont J, Fizazi K, Hecker H, Kanz L, Einhorn L, Bokemeyer C (2001) Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93: 1733–1738
Heidenreich A (2009) Contralateral testicular biopsy in testis cancer: current concepts and controversies. BJU Int 104: 1346–1350
Heidenreich A, Albers P (2009) [Ablatio testis and enucleation resection].[Article in German]. Aktuelle Urol 40: 179–187
Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, Dieckmann KP (2001) Organ Sparing Surgery for malignant Germ Cell Tumors of the Testis. J Urol 166: 2161–2165
Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A (2005) Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol 44: 529–536
Hernes EH, Harstad K, Fosså SD (1996) Changing incidence and delay of testicular cancer in southern Norway (1981–1992). Eur Urol 30: 349–57
Herr HW, Sheinfeld J (1997) Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urol 158: 1331–1334
Hoei-Hansen CE, Holm M, Rajpert-De Meyts E, Skakkebaek NE (2003) Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 200: 370–374
Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868
Howard GC, Nairn M (2011) Management of adult testicular germ cell tumours: summary of updated SIGN guideline. BMJ 342: d2005
Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP (2005) Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93: 200–207
Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud JM, Plante P, Bujan L, Thonneau P (2004) Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100: 732–737
Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P (2007) Impact of diagnostic delay in testis cancer: Results of a large population based study. Eur Urol 52: 1710–1716
Huyghe E, Soulie M, Escourrou G, Mieusset R, Plante P, Thonneau P (2005) Conservative management of small testicular tumors relative to carcinoma in situ prevalence. J Urol 173: 820–823
Incrocci L, Bosch JL, Slob AK (1999) Testicular prostheses: body image and sexual functioning. BJU Int 84: 1043–1045
Kirkham AP, Kumar P, Minhas S, Freeman AA, Ralph DJ, Muneer A, Allen C (2009) Targeted testicular excision biopsy: when and how should we try to avoid radical orchidectomy? Clin Radiol 64: 1158–1165
Kliesch S (2003) Fertilität bei Patienten mit Hodenerkrankungen. Onkologe 9: 955–961
Kliesch S (2004) Diagnostik und Primärtherapie des Hodentumors. Urologe A 43: 1494–1499
Kliesch S, Kamischke A, Nieschlag E (2000) Kryokonservierung menschlicher Spermien zur Zeugungsreserve. In Andrologie. Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, Nieschlag E, Behre HM (eds) 2. Aufl, pp 407–416. Berlin: Springer Verlag
Kliesch S, Thomaidis T, Schütte B, Puhse G, Kater B, Roth S, Bergmann M (2003) Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS 111: 70–74
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496
Lambert SM, Fisch H (2007) Infertility and testis cancer. Urol Clin North Am 34: 269–277
Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15: 239–245
Lee EK, Holzbeierlein JM (2009) Management of the contralateral testicle in patients with unilateral testicular cancer. World J Urol 27: 421–426
Leibovitch I, Baniel J, Foster RS, Donohue JP (1995) The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol 154: 935–939
Leroy X, Rigot JM, Aubert S, Ballereau C, Gosselin B (2003) Value of frozen section examination for the management of nonpalpable incidental testicular tumors. Eur Urol 44: 458–460
Magelssen H, Haugen TB, von During V, Melve KK, Sandstad B, Fosså SD (2005) Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol 48: 779–785
Mortensen MS, Gundgaard MG, Daugaard G (2011) Treatment options for carcinoma in situ testis. Int J Androl 34: e32–e36
Moul JW (2007) Timely diagnosis of testicular cancer. Urol Clin North Am 34: 109–117
Nikzas D, Champion AE, Fox M (1990) Germ cell tumours of testis: prognostic factors and results. Eur Urol 18: 242–7
Pizzocaro G, Guarneri A (2009) Inguinal orchidectomy for testicular cancer. BJU Int 103: 704–716
Prym C, Lauke H (1994) Carcinoma -in-situ of the human testis: Tumour cells are distributed focally in the seminiferous tubules. Andrologia 26: 231–234
Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW (2008) Histological Outcome of Delayed Orchidectomy after Primary Chemotherapy for Metastatic Germ Cell Tumour of the Testis. Clin Oncol (R Coll Radiol) 20: 247–252
Richie JP (1984) Simultaneous bilateral tumors with unorthodox management. World J Urol 2: 74
Schmidt KL, Carlsen E, Andersen AN (2007) Fertility treatment in male cancer survivors. Int J Androl 30: 413–418
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group, Collaborators, (63) (2010) Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v147–v154
Scholz M, Zehender M, Thalmann GN, Borner M, Thoni H, Studer UE (2002) Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol 13: 121–124
Seppelt U (1982) Enukleation eines sukzessiven Zweittumors im Resthoden. Therapiewoche 32: 560–563
Sibert L, Rives N, Rey D, MacE B, Grise P (1999) Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 84: 1038–1042
Steiner H, Höltl L, Maneschg C, Berger AP, Rogatsch H, Bartsch G, Hobisch A (2003) Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology 62: 508–513
Taksey J, Bissada NK, Chaudhary UB (2003) Fertility after chemotherapy for testicular cancer. Arch Androl 49: 389–395
Ulbright TM (2008) The Most Common, Clinically Significant Misdiagnoses in Testicular Tumor Pathology, and How to Avoid Them. Adv Anat Pathol 15: 18–27
van Casteren NJ, Boellaard WP, Dohle GR, Weber RF, Kuizinga MC, Stoop H, Oosterhuis WJ, Looijenga LH (2008) Heterogeneous distribution of ITGCNU in an adult testis: consequences for biopsy-based diagnosis. Int J Surg Pathol 16: 21–24
von der Maase H (2005) Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol 44: 523–525
von der Maase H, Giwercman A, Müller J, Skakkebaek NE (1987) Management of carcinoma-in-situ of the testis. Int J Androl 10: 209–220
Weissbach L, Janssen PL, Bach D (1979) Die Implantation von Hodenprothesen unter Berücksichtigung psychischer Aspekte. Urologe A 18: 151–156
Weissbach L, Schaefer C (2008) Organerhaltende Hodentumorchirurgie. Urologe 47: 809–817
Winter E, Kliesch S, Souchon R, De Wit M (2005) Diagnostik des Hodentumors. Dtsch Ärztebl 102: A3021–A3025
Wittekind C (2008) Biologie und Pathologie von Keimzelltumoren des Hodens. Onkologe 14: 602–610
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P (2010) Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4: e19–e38
Yossepowitch O, Aviv D, Wainchwaig L, Baniel J (2011) Testicular prostheses for testis cancer survivors: patient perspectives and predictors of long-term satisfaction. J. Urol 186.: 2249–2252
Yossepowitch O, Baniel J (2004) Role of organ-sparing surgery in germ cell tumors of the testis. Urology 63: 421–427
Zuniga A, Lawrentschuk N, Jewett MA (2010) Organ-sparing approaches for testicular masses. Nat Rev Urol 7: 454–464
Literatur zu ▶ Abschn. 25.6
Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G, Jørgensen N (2009) Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 75: 672–676
Bart J, Groen HJ, van der Graaf WT, Hollema H, Hendrikse NH, Vaalburg W, Sleijfer DT, de Vries EG (2002) An oncological view on the blood-testis barrier. Lancet Oncol 3: 357–363
Buchler T, Freeman A, Harland S (2008) Contralateral intratubular germ cell neoplasia in a patient with testicular cancer. Nat Clin Pract Urol 5: 284–288
Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657–660
Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V, Group. GTCS (2003) Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 88: 828–831
Corona G, Rastrelli G, Forti G, Maggi M (2011) Update in Testosterone Therapy for Men (CME). J Sex Med 8: 639–654
Dieckmann K-P, Claßen J, Loy V (2005) Präkanzerose der Hodentumoren: Testikuläre intraepitheliale Neoplasie. Dtsch Ärztebl 102: A3106–A3109
Dieckmann KP, Kliesch S (2010) Therapie der Testikulären Intraepithelialen Neoplasie (TIN) – eine multizentrische Studie der German Testicular Cancer Study Group. Urologe 49: 24, abstract # V7.3
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) Diagnosis of Contralateral Testicular Intraepithelial Neoplasia (TIN) in Patients with Testicular Germ Cell Cancer: Systematic two-Site biopsies are more sensitive than a single Random Biopsy. Eur Urol 51: 175–185
Dieckmann KP, Lauke H, Michl U, Winter E, Loy V (2002) Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur Urol 41: 643–649
Dieckmann KP, Loy V (1995) Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 28: 25–30
Dieckmann KP, Loy V (1998) The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS 106: 13–20
Fraietta R, Spaine DM, Bertolla RP, Ortiz V, Cedenho AP (2010) Individual and seminal characteristics of patients with testicular germ cell tumors. Fertil Steril 94: 2107–2112
Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A, Skakkebaek NE (1991) Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 73: 596–603
Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868
Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V, Weissbach L (2009) Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology 77: 33–39
Kliesch S, Bergmann M, Hertle L, Nieschlag E, Behre HM (1997) Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. Hum Reprod 12: 2830–2835
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496
Mortensen MS, Gundgaard MG, Daugaard G (2011) Treatment options for carcinoma in situ testis. Int J Androl 34: e32–e36
Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkebaek NE, Hansen SW, von der Maase H (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 20: 1537–1543
Rajpert-De Meyts E, Hoei-Hansen CE (2008) From Gonocytes to Testicular Cancer: The Role of Impaired Gonadal Development. Ann N Y Acad Sci 1120: 168–180
Schmidt KL, Carlsen E, Andersen AN (2007) Fertility treatment in male cancer survivors. Int J Androl 30: 413–418
Sedlmayer F, Höltl W, Kozak W, Hawliczek R, Gebhart F, Gerber E, Joos H, Albrecht W, Pummer K, Kogelnik HD, (AUO). TAU-OG (2001) Radiotherapy of testicular intraepithelial neoplasia (TIN): a novel treatment regimen for a rare disease. Int J Radiat Oncol Biol Phys 50: 909–913
Skakkebaek NE (2004) Testicular dysgenesis syndrome: New epidemiological evidence. Int J Androl 27: 189–191
Souchon R, Gertenbach U, Dieckmann KP, Hahn E, Ruwe M, Stambolis C, Loy V, Classen J (2006) Contralateral Testicular Cancer in spite of TIN-Negative Double Biopsies and Interval Cisplatin Chemotherapy. Strahlenther Onkol 182: 289–292
Literatur zu ▶ Abschn. 25.7
Albers P (2012) [Retroperitoneal lymphadenectomy - pro robotic.] Urologe A. 2012 Apr 27 [Epub ahead of print] (in German)
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP (2011) EAU Guidelines on Testicular Cancer: 2011 Update.. Eur Urol 2011;60:304–319
Albers P, Bender H, Yilmaz H et al. (1999) Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology 53: 808–811
Alexander EJ, White IM, Horwich A (2010) Update on management of seminoma. Indian J Urol 26: 82–91
American College of Radiology (2009) ACR Appropriateness Criteria: Staging of testicular malignancy. 2009 [http.//acr.org]
Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR; Spanish Germ Cell Cancer Cooperative Group (GG) (2003) Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14: 867–872
Aparicio J, Germa JR, Del Muro XG, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, Lopez-Brea M, Sanchez A (2005) Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 23: 817–823
Aparicio j, Garcia-Puche j, Lomas M, et al. (2006) Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: a multivariate analysis on 588 cases. J Clin Oncol 24; 229s
Aparicio J, Robert L, Garcia del Muro X, et al. (2010) Risk-adapted mamagement of stage I seminoma: results of the third Spanish Germ Cell Cancer Group study. J Clin Oncol 28(7S): abstract 4532.
Aparicio J, Maroto P, Garcia del Muro X, et al. (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol; 29: 4677–4681
Bamberg M, Schmidberger H, Meisner C et al. (1999) Radiotherapy for stage I, IIA/B testicular seminoma. Int J Cancer 83: 823–827
Baniel J, Foster RS, Gonin R et al. (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176
Barth V, Hums R (1990) Serumhormone und Spermiogrammveränderungen bei Patienten mit malignen Hodentumoren nach Strahlen- und Zytostatikatherapie. Z Urol Nephrol 83: 291–295
Beard C, Chen M, Arvold ND, Nguyen PL, Ng AK, Hoffman KE (2011) Long-term survival and competing causes of death in men with stage I seminoma. J Clin Oncol 29 (No 7_suppl (March 1 Supplement). 2011:226
Berrington de Gonzalez A, Mahesh M, Kim KP, et al. (2009) Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 169: 2071–2017
Borski A (1973) Diagnosis, staging and natural history of testicular seminoma. Cancer 32: 1202–1206
Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F (2011) Trends in mortality from urologic cancers in europe, 1970-2008. Eur Urol 60: 1–15
Bosl GJ, Patil S (2011) Carboplatin in clinical stage I seminoma: too much and too little at the same time J Clin Oncol 29: 949–952
Brenner DJ, Elliston CD (2004) Estimated radiation risks potentially associated with full-body CT screening. Radiology 232: 735–738
Brenner DJ, Hall EJ (2007) Computed tomography – an increasing source of radiation exposure. N Engl J Med 357: 2277–2284
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O; Norwegian Urology Cancer Group III study group (2010) Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58 (1): 134–40 [Epub 2010 Apr 2]
Busch FM, Sayegh ES, Shenault OW Jr. (1965) Some uses of lymphangiography in the management of testicular tumors. J Urol 93: 490–495
Cabot H, Berkson J (1939) Neoplasms of the testis: a study of the results of orchidectomy, with and without irradiation. New Engl J Med 220: 192–195
Capelouto CC, Clark PE, Ransil BJ et al. (1995) A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary? J Urol 153: 981–985
Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S (2011) Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 34:59–64
Chaganti RSK, Houldsworth J (2000) Genetics and biology of adult human germ cell tumors. Cancer Res 60: 1475–1482
Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, Danjoux C, Klotz L, Morton G, Chander S (2005) Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61: 736–740
Chung P, Warde P (2011a) Stage I seminoma: adjuvant treatment is effective but is it necessary? J Natl Cancer Inst 103:194–196
Chung P, Warde P (2011b) Testicular cancer: seminoma. Clin Evid (Online) 2011 Jan 25;2011. pii: 1807.
Chung PW, Daugaard G, Tyldesley S, et al. (2010a) Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol 2010:28:15s, 2010 (suppl; abstr 4535)
Chung P, Mayhew LA, Warde P, Winquist E, Lukka H; Genitourinary Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2010b) Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 22:6–16
Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90: 2305–2311
Classen J, Souchon R, Hehr T, Bamberg M (2001) Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol 127:475–481
Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. APMIS 111: 76–83
Deutsche Krebsgesellschaft e. V. (2002) Qualitätssicherung in der Onkologie – Leitlinie zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). In: Souchon R, Schmoll H-J, Krege S (Hrsg) Zuckschwerdt, München
Dieckmann KP, Brüggeboes B, Pichlmeier U et al. (2000) Adjuvant treatment of clinical stage I seminoma: Is one single course of carboplatin sufficient? Urology 55: 102–106
Dieckmann KP, Krain J, Küster J et al. (1996) Adjuvant carboplatin treatment for seminoma clinical stage I. J Cancer Res Clin Oncol 122: 63–66
Ferlay J, Bray F, Pisani P et al. (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5, Lyon: IARC 2001 (auch: www.iarc.fr/globocan/database.pdf)
Fitzgerald R, Twiss D, Mehra R, Evans M, Qaiyum M, Collins M (2004) Low-dose computed tomography surveillance of patients with testicular tumours. Clin Oncol (R Coll Radiol) 16: 158
Fosså SD (2004) Long-term sequelae after cancer therapy – survivorship after treatment for testicular cancer. Acta Oncol 43: 134–141
Fosså SD, Abyholm T, Vespestad S et al. (1993) Semen quality after treatment for testicular cancer. Eur Urol 23: 172–176
Fosså SD, Horwich A, Russel JM et al. (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 117: 1146–1154
Fosså SD, Aass N, Winderen M, Bormer OP, Olsen DR (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13: 222–228
Fosså SD;Johannesen TB;Lehne G (2006) Long-term outcome after adult-onset cancer. Ann Oncol 17 Suppl 10:X292–98
Fosså SD, Gilbert E, Dores GM et al. (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99: 533–544
Fosså SD, Cvancarova M, Chen L, et al. (2011) Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol 29: 963–970
Francis R, Bower M, Brunstrom G, Holden L, Newlands ES, Rustin GJ, Seckl MJ (2000) Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36: 1925–1932
Fung C, Fosså SD, Beard CJ, Travis LB (2012) Second malignant neoplasms in testicular cancer survivors. J Natl Compr Canc Netw 10: 545–556
Gatta G, Ciccolallo L, Kunkler I et al., EUROCARE Working Group (2006). Survival from rare cancer in adults: a population-based study. Lancet Oncol 7: 132–140
Germa-Lluch JR, Climent MA, Villavicencio H et al. (1993) Br J Urol 71: 473–477
Hansen J, Jurik AG (2009) Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. Acta Radiol 50: 1064–1070
Haugnes HS, Aass N, Fosså SD, Dahl O, Brydøy M, Aasebø U, Wilsgaard T, Bremnes RM (2009) Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27 (17): 2779–86 [Epub 2009 May 4]
Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fosså SD (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28 (30): 4649-57 [Epub 2010 Sep 20]
Haugnes HS, Wethal T, Aass N, et al. (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28: 4649–4657
Hentrich M, Meiler S, Fegg M, Gerl A (2008) Changes in sexual functioning after germ cell tumor (GCT) therapy estimated by patients and their partners. J Clin Oncol 26: May 20 suppl; abstr 5086
Horwich A (2004) Radiotherapy in stage I seminoma of the testis. J Clin Oncol 22: 585–588
Horwich A, Alsanjari N, A’Hern R, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65: 775–778
Horwich A, Dearnaley D, Hern RA et al. (1992) Activity of single agent Carboplatin in advanced seminoma. Eur J Cancer 28-A: 1307–1310
Horwich A, Fosså SD, Stenning SP, Bliss JM, Hall E (2010) Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. J Clin Oncol 28:15s (suppl; abstr 4538)
Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367(9512): 754–65
Huddart R, Kataja V (2008) ESMO Guidelines Working Group. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol; 19 Suppl 2: ii49–51
Huddart RA (2010) Stage I germ cell tumours: achieving cure at minimal cost. Clin Oncol (R Coll Radiol) 22: 1–5
Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11
Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME (2012) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol 187 (2): 487-92 [Epub 2011 Dec 16
Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893–1907
Jones WG, Fosså SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200–1208
Joos H, Sedlmayer F, Gomahr A et al. (1997) Endokrine profiles after radiotherapy in stage I seminoma: impact of two different radiation treatment modalities. Radiother Oncol 43: 159–162
Kleinschmidt K, Dieckmann KP, Georgiew A, et al. (2009) Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology 77: 33–39
Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21 (6): 1296-301 [Epub 2009 Oct 29]
Krege S, Beyer J, Souchon R et al. (2008a) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53: 478–496
Krege S, Beyer J, Souchon R et al. (2008b) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53: 497–513
Krege S, Kalund G, Otto T et al. (1997) Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 31: 405–407
Lassen U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402
Lewinshtein D, Porter CR (2010) Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy.J Clin Oncol 28:15 s, 2010 (suppl; abstr 4537)
Loehrer PJ Sr, Bosl GJ (2005) Carboplatin for stage I seminoma and the sword of damocles. J Clin Oncol 24: 467–475
Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G (2003) Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 57: 1304–1309
Lombardi M, Valli M, Brisigotti M, Rosai J (2011) Spermatocytic seminoma: review of the literature and description of a new case of the anaplastic variant. Int J Surg Pathol 19: 5–10
Looijenga LH, Hersmus R, Gillis AJ, Pfundt R, Stoop HJ, van Gurp RJ, Veltman J, Beverloo HB, van Drunen E, van Kessel AG, Pera RR, Schneider DT, Summersgill B, Shipley J, McIntyre A, van der Spek P, Schoenmakers E, Oosterhuis JW (2006) Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res 66: 290–302
Looijenga LHJ, Stoop H, Hersmus R, Gillis AJM, Oosterhuis JW (2007) Genomic and expression profiling of human spermatocytic seminomas: pathogenetic implications. Int J Androl 30: 328–336
Majewski W, Majewski S, Maciejewski A, Kolosza Z, Tarnawski R (2005) Adverse effects after radiotherapy for early stage (I, IIa, IIb) seminoma. Radiother Oncol 2; 76: 257–63
Mason M, Jones W (1997) Treatment of stage I seminoma: more choice, more dilemmas. Clin Oncol 9: 210–212
Mason MD, Featherstone T, Olliff J Horwich A (1991) Inguinal and iliacal lymph node involvement in germ cell tumours of the testis: Implications for radiological investigation and for therapy. Clin Oncol 3: 147–150
McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97: 63–70
Mead GM, Fosså SD, Oliver RT, Joffe JK, Huddart RA, Roberts JT, Pollock P, Gabe R, Stenning SP; MRC/EORTC seminoma trial collaborators (2011) Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 103: 241–249.
Mottet N, Rousmans S, Culine S (2008) Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy. Bull Cancer 95: 205–234
Nathan PD, Rustin GR (2003) The role of CT scanning in the surveillance of testicular tumours. Clin Oncol (R Coll Radiol) 15: 121–122
National Comprehensive Cancer Network (NCCN) (2011) NCCN Guidelines – Testicular cancer. V2.2011. http://www.nccn.org
Oldenburg J, Martin JM, Fosså SD (2006) Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 24:5503–5511
Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, De Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 collaborators and the EORTC 30982 collaborators (2005b) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366: 293–300
Oliver RT, Mead GM, Fogarty PJ, Stenning SP, MRC TE19 and EORTC 30982 trial collaborators (2008) Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26: 20 suppl, abstr 1
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214) (2011). J Clin Oncol 29: 957–962.
Oliver RTD, Boublikova L, Ong J (2001) Fifteen year follow up of the anglian germ cell cancer group adjuvant studies of carboplatin as an alternativ to radiation or surveillance for stage 1 seminoma. Proc Am Soc Clin Oncol 20: 196a. Abstract #780
Oliver RTD, Edmonds PM, Ong J et al. (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29: 3–8
Oliver RTD, Lore SH, Ong J (1990) Alternatives to radiotherapy in the management of seminoma. Br J Urol 65: 61–67
Oliver T, Dieckmann K-P, Steiner H, Skoneczna I (2005a) Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma. J Clin Oncol 23, No16S, Part I: 395s. Abstract #4572
Oxford Centre for Evidence based Medicine (2001) Levels of evidence. http://minerva.minervation.com/cebm/
Petersen PM, Giwercman A, Skakkebaek NE, Rorth M (1998) Gonadal function in men with testicular cancer. Semin Oncol 25: 224–233
Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 9: 443–447
Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115: 822–827
Ramakrishnan S, Champion AE, Dorreen MS, Fox M (1992) Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) 4: 284–286
Ray B, Hajdu SI, Whitmore WF (1974) Distribution of retroperitoneal lymph node metastases in germinal tumors. Cancer 33: 340–348
Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nöst G, Lipsky H, Marberger M, Kratzik C (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19: 101–104
Robert-Koch-Institut (2010). Verbreitung von Krebserkrankungen in Deutschland. Hodenkrebs. http://www.rki.de/cln_169/nn_1869836/DE/Content/GBE/DachdokKrebs/Praevalenz/Lokalisationen/C62.pdf
Robinson D, Møller H, Horwich A (2007) Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007; 96: 529–533
Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25 (11): 1310–5
Schairer C, Hisada M, Chen BE, Brown LM, Howard R, Fosså SD, Gail M, Travis LB (2007) Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 99: 1248–1256
Schmidberger H, Bamberg M (1995) Therapieoptionen bei testikulären Seminomen in den frühen Stadien. Strahlenther Onkol 171: 125–139
Schmidberger H, Virsik-Koepp P, Rave-Frank M, Reinosch KR, Pradier O, Munzel U, Hess CF (2001) Reciprocal translocations in patients with testicular seminoma before and after radiotherapy. Int J Radiat Oncol Biol Phys 50: 857–864
Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm Ch, Berdel W, Souchon R, Schöber Ch, Wilke H, Poliwoda H (1993) Single agent carboplatinum for advanced seminoma: a phase II study. Cancer 72: 237–243
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v140–146
Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399
Scottish Intercollegiate Guidelines Network (SIGN) (2011) Management of adult testicular germ cell tumours. A national clinical guideline 124. http://www.sign.ac.uk/pdf/sign124.pdf
Smith-Bindman R, Lipson J, Marcus R, et al. (2009) Radiation dose associated with common computed tomography examinations and the associated attributable risk of cancer. Arch Intern Med 169: 2078–2086
Sobin LH, Gospodarowiwicz, Wittekind C (eds.) (2009) UICC: TNM classification of malignant tumours, 7th edition. John Wiley & Sons, New York
Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, Horwich A, Huddart R (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64: 362–367
Souchon R, Krege S, Schmoll HJ, Albers P, Beyer J, Bokemeyer C, Claßen J, Diekmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M für die German Testicular Cancer Study Group (GTCSG) (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Strahlenther Onkol 176: 388–405
Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ (2002) The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. Brit J Urol Int 89: 549–556
Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 30 (3): 300–7 [Epub 2011 Dec 19]
Statistisches Landesamt Saarland (2002) Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland, Häufigkeiten und Trends. 3. erweiterte aktualisierte Auflage. Saarbrücken
Steiner H, Höltl L, Wirtenberger W, Berger AP, Bartsch G, Hobisch A (2002) Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 60: 324–328
Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, Warde PR, Gospodarowicz MK, Alison RE, Liu J, Ma C, Pond GR, Jewett MA (2010) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol 59 (4): 556-62 [Epub 2010 Dec 22]
Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27 (13): 2122–8 [Epub 2009 Mar 23] Erratum in: J Clin Oncol 2009 27 (19): 3263, J Clin Oncol 2010 28 (8): 1438; Dosage error in article text
Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 29: 719–725.
Thomas GM (1996) Para-aortic radiotherapy for stage I seminoma: a new standard. Int J Radiat Oncol Biol Phys 35: 413–414
Thorsen L, Nystad W, Stigum H, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD (2005) The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 13: 637–646
Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fosså SD (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102:1114–1130
Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429–1439
Travis LB, Fosså SD, Schonfeld SJ et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365
TRISST (MRC TE24) Trial of imaging and schedule in seminoma testis. http://www.ctu.mrc.ac.uk/svtudies/TE24.asp
UICC (International Union Against Cancer) (2006) Prognostic factors. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Cancer. 3rd ed. Lavoisier
Underwood W, Kim HL (2012) Intermediate-term oncological efficacy of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell testicular cancer. BJU Int 109 (2): 281–5 [doi: 10.1111/j.1464-410X.2011.10290.x. Epub 2011 Jun 1]
van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA (2008) Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 98: 1894–1902
van den Belt-Dusebout AW, de Wit R, Gietema JA et al. (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370–4378
von der Maase H (1999). UICC-Symposium on Testicular Cancer, Tübingen, Abstractband, pp 21–22
von der Maase H, Rorth M, Walbom-Jorgensen S et al. (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293: 1398–401
von der Maase H, Warde p, Specht L et al. (1998) Prognostic factors for relapse following surveillance in seminoma stage I patients. Radiother Oncol 48: Suppl 1: 11, Abstract #42
Warde P, Gospodarowicz M (2005) Adjuvant carboplatin in stage I seminoma. Lancet 366: 267–268
Warde P, Gospodarowicz M (2009) Evolving concepts in stage I seminoma. BJU Int 104:1357–1361
Warde P, Gospodarowicz M, Panzarella T et al. (1998b) Management of stage II seminoma. J Clin Oncol 16: 290–294
Warde P, Gospodarowicz MK, Banerjee D et al. (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705–1710
Warde P, Gospodarowicz MK, Panzarella T et al. (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13: 2255–2262
Warde P, Jewett MAS (1998) Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 25: 425–433
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance. J Clin Oncol 20: 4448–4452
Warde P, von der Maase H, Horwich A et al. (1998a) Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 17: 309a. Abstract #1188
Warde PR, Chung P, Sturgeon J, Panzarella T, Giuliani M, Tew-George B, Jewett M, Bayley A, Moore M, Catton C, Gospodarowicz M (2005) Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol 23: 382S Part 1 Suppl. S. Abstract #4520
Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138: 77–82
Weissbach L, Bussar-Maatz R, Löhrs U et al. (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36: 601–608
Williams SB, Lau CS, Josephson DY (2011) Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. Eur Urol 60 (6): 1299-302 [Epub 2011 Mar 21]
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P (2010) Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4: e19–38
Yoshida T, Kakimoto K, Takezawa K, et al. (2009) Surveillance following orchiectomy for stage I testicular seminoma: long-term outcome. Int J Urol 16: 756–759
Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647
Zwahlen DR, Martin JM, Millar JL, Schneider U (2008) Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 70: 853–858
Literatur zu ▶ Abschn. 25.8
Albers P (2012) Retroperitoneal lymphadenectomy – pro robotic. Urologe A 51 (5): 687–691
Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Muller SC (1997) MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79 (9): 1710–1716
Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC (1999) Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 53 (4): 808–811
Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M (2003) German Testicular Cancer Study Group Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21: 1505–1512
Albers P, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I non-seminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26 (18): 2966–72
Amato RJ, Ro JY, Ayala AG, Swanson DA (2004) Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63: 144–8; discussion 148–149
Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, Lopez-Brea M, Sanchez A (2005) The Second Spanish Germ Cell Cancer Cooperative Group. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23: 8717–8723
Baniel J, Foster RS, Rowland RG et al. (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152 (2 Pt 1):424–427
Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11 (9): 1703–1709
Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14 (11): 2923–2932
Boyer M, Raghavan D (1992) Toxicity of treatment of germ cell tumors. Semin Oncol 19 (2): 128–142
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O; Norwegian Urology Cancer Group III study group (2010) Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58 (1): 134–40
Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L, Plante P, Rischmann P, Bachaud JM, Malavaud B (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214
Corti Ortiz D, Foneron Burgos A, Troncoso Schifferli L (1997) Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy. Actas Urol Esp 21 (10): 961–963
Cullen MH, Stenning SP, Parkinson MC et al. (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14 (4): 1106–1113
De Riese WT, De Riese C, Ulbright TM et al. (1994) Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. Int J Cancer 57 (5): 628–633
De Wit M, Hartmann J, Kotzerke M, Wirth W, Brenner D, Hellwig J, Lehmann R, Heicappell C, Bokemeyer R, Bares (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol 23:4504 (supplement)
Dearnaley DP, Fosså SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, Graham JD, Roberts JT, Mead GM, Williams MV, Cook PA, Stenning SP (2005) for the MRC Testicular Tumour Working Party. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective tiral (MRC TE17). Br J Cancer 92:2107–2113
Donohue JP, Thornhill JA, Foster RS et al. (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 71 (3): 326–35
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A (10): 1599–1604
Duran I, Sturgeon JF, Jewett MA, Anson-Cartwright L, Berthold DR, Kakiashvili D, Warde PR, Alison RE, Pond GR, Moore MJ (2007) Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 25, No 18S :5021 (abstract)
Fosså SD, Jacobsen AB, Aass N et al. (1994) How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources? Br J Cancer 70 (6): 1156–1160
Freedman LS, Parkinson MC, Jones WG et al. (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2 (8554): 294–298
Gels ME, Hoekstra HJ, Sleijfer DT et al. (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13 (5): 1188–1194
Hain SF, O’Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27 (5): 590–594
Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fosså SD (2010) Cardiovsacular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28 (30): 4649–57
Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83 (5): 1002–1011
Heidenreich A, Albers P, Kliesch S et al. (2002) Morbidity of primary nerve-sparing retroperitoneal lymph node dissection in clinical stage I nonseminomatous testis cancer. Journal of Urology 167 (4):154 (Abstract)
Hendry WF, Norman A, Nicholls J, Dearnaley DP, Peckham MJ, Horwich A (2000) Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 86 (1): 89–93
Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME (2012) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol 187 (2): 487–92
Janetschek G (2001) Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 28 (1):107–114
Janetschek G, Hobisch A, Peschel R et al. (2000) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 163 (6):1793–6
Janetschek G, Peschel R, Hobisch A, Bartsch G (2001) Laparoscopic retroperitoneal lymph node dissection. J Endourol 15 (4):449–53; discussion 453–455
Klepp O, Dahl O, Flodgren P et al. (1997) Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 33 (7): 1038–1044
Kollmannsberger C, Beyer J, Droz JP et al. (1998) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16 (10): 3386–3391
Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21 (6): 1296–301
Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M (2003) Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 30:396–402
Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16 (1): 261–268
Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54 (2): 362–364
Nelson JB, Chen RN, Bishoff JT et al. (1999) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urol 54 (6):1064–7
Nielsen ME, Lima G, Schaeffer EM, Porter J, Cadeddu JA, Tuerk I, Kavoussi LR (2007) Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology 70: 1168–72
Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel AI, van Roon AM, Gietema JA (2005) Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23: 9130–9137
Oliver RT, Raja MA, Ong J, Gallagher CJ (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148: 1453–5; discussion 1455–1456
Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay J, Robinson A, Neal DE, Williams M (2004) for the Anglian Germ Cell Cancer Group. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urol 63:556–561
Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33 (6): 562–566
Pectasides D, Skarlos D, Dimopoulos AM, Farmakis D, Pectasides M, Fountzilas G, Aravantinos G (2003) Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 23: 4239–4244
Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 (2): 441–448
Rassweiler JJ, Frede T, Lenz E et al. (2000) Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 37 (3):251–260
Read G, Stenning SP, Cullen MH et al. (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10 (11): 1762–1768
Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25 (11): 1310–1315
Schefer H, Mattmann S, Borner M et al. (2000) Single course adjuvant bleomycin, etoposide and cisplatin (BEP) for high risk stage I non-seminomatous germ cell tumors (NSGCT). Proc ASCO 19: 340a
Sharir S, Jewett MA, Sturgeon JF et al. (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161 (2): 472–475; discussion 475–476
Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G (1998) Clinical stage I testis cancer: long-term outcome of patients on surveillance [see comments]. J Urol 159 (3): 855–858
Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 30 (3): 300–307
Studer UE, Burkhard FC, Sonntag RW (2000) Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage i nonseminomatous germ cell tumor. J Urol; 163 (6): 1785–1787
Sturgeon JF, Jewett MA, Alison RE et al. (1992) Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10 (4): 564–568
Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, Warde PR, Gospodarowicz MK, Alison RE, Liu J, Ma C, Pond GR, Jewett MA (2011) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol 59 (4): 556–562
Swanson D, Johnson DE (1989) M. D. Anderson experience with surveillance for clinical stage I disease. In: Johnson DE, Logothetis CJ, von Eschenbach AC (eds) Systemic therapy for genitourinary cancers. Year Book Medical Publishers, Chicago, pp 304–311
Tandstad T, Olav D, Cohn-Cedermark G, Cavallin-Stahl E, Stierner UK, Solberg A, Bremnes RM, Langberg CW, Klepp OH (2008) Risk-adapted treatment in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT) J Clin Oncol 26 abstr 5034
Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27 (13): 2122–2128
Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer [see comments]. J Natl Cancer Inst 89 (19): 1429–1439
Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365
Underwood W, Kim HL (2012) Intermediate-term oncological efficacy of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell testicular cancer. BJU Int109 (2): 281–285
Van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BMP, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (28):4370–4378
Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21:4092–4099
Westermann DH, Schefer H, Thalmann GN, Karamitopoulou-Diamantis E, Fey MF, Studer UE (2008) Long-term follow-up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I non-seminomatous germ cell tumors of the testis. J Urol 179: 163–166
Williams SB, Lau CS, Josephson DY (2011) Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. Eur Urol 60 (6): 1299–1302
Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647
Literatur zu ▶ Abschn. 25.9
Albers P, Bender H, Yilmaz H et al. (1999) Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors. Urology 53: 808–811
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna MP, Pizzocaro G (2005) Guidelines on Testicular Cancer. Eur Urol 48: 885–894
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP (2011) EAU Guidelines on Testicular Cancer: 2011 Update. Eur Urol 60: 304–19
Arranz Arija JA, García del Muro X, Gumà J et al. (2001) E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience. Ann Oncol 12: 487–491
Ball D, Barrett A, Peckham MJ (1982) The management of metastatic seminoma testis. Cancer 50: 2289–2294
Bamberg M, Schmidberger H, Meisner C et al. (1999) Radiotherapy for stage I, IIA/B testicular seminoma. Int J Cancer 83: 823–827
Borski A (1973) Diagnosis, staging and natural history of testicular seminoma. Cancer 32: 1202–1206
Busch FM, Sayegh ES, Shenault OW Jr. (1965) Some uses of lymphangiography in the management of testicular tumors. J Urol 93: 490–495
Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S (2011) Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 34: 59–64
Chung PW, Gospodarowicz MK, Panzarella T et al. (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45: 754–759
Classen J, Schmidberger H, Meisner C et al. (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21: 1101–1106
Classen J, Schmidberger H, Meisner C et al. (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90: 2305–2311
Deutsche Krebsgesellschaft e. V. (2002) Qualitätssicherung in der Onkologie – Leitlinie zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). In: Souchon R, Schmoll H-J, Krege S (Hrsg) Zuckschwerdt, München
Ferlay J, Bray F, Pisani P et al. (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5, Lyon: IARC 2001 (auch: www.iarc.fr/globocan/database.pdf)
Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, López Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, Pérez X, Germá-Lluch JR (2008) Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 26: 5416–21
Garcia-del-Muro X, Germá-Lluch JR (2009) in reply to: Gilbert DC, Van As NJ, Beesley S, Bloomfield D, Money-Kyrle J, Norman A, Dearnaley D, Horwich A, Huddart RA. Treating IIA/B seminoma with combination carboplatin and radiotherapy. J Clin Oncol 2009;27: 2101–2102. www.jco.org on March 16, 2009
Gilbert DC, Van As NJ, Beesley S, Bloomfield D, Money-Kyrle J, Norman A, Dearnaley D, Horwich A, Huddart RA (2009) Treating IIA/B seminoma with combination carboplatin and radiotherapy. J Clin Oncol 27: 2101–2102
Gospodarowicz MK, Sturgeon JFG, Jewett MAS (1998) Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol 25: 160–173
Huddart R, Kataja V (2008) ESMO Guidelines Working Group. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2: ii49–51
Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11
Jones WG, Fosså SD, Mead GM et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200–1208
Krege S, Souchon R, Schmoll HJ (2001) Interdisciplinary Consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 40: 372–391
Krege S, Boergemann C, Baschek R et al. (2006) Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 17: 276–280
Krege S, Beyer J, Souchon R et al. (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I+II. Eur Urol 53: 478–496 + 497–513
Krug B, Heidenreich A, Dietlein M et al. (1999) Lymphknotenstaging maligner testikulärer Keimzelltumoren. Fortschr Röntgenstr 171: 87–94
Lashley D, Lowe B (1998) A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 25: 405–423
Lassen U, Daugaard G, Eigtved A et al. (2003) Wholebody positron emission tomography (PET) with FDG in patients with stage I non-seminomatous germ cell tumours (NSGCT). Eur J Nucl Med Imaging 30: 396–402
Leibovitch I, Foster RS, Kopecky KK et al. (1995) Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol 154: 1759–1763
Leibovitch I, Foster RS, Kopecky KK et al. (1998) Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16: 261–268
Mead GM, Fosså SD, Oliver RT, Joffe JK, Huddart RA, Roberts JT, Pollock P, Gabe R, Stenning SP; MRC/EORTC seminoma trial collaborators (2011) Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 103: 241–249.
Milosevic MF, Gospodarowicz M, Warde P (1999) Management of testicular seminoma. Semin Surg Oncol 17: 240–249
National Comprehensive Cancer Network – NCCN (2011) NCCN Guidelines – Testicular cancer. V2.2011. [http://www.nccn.org]
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214) (2011). J Clin Oncol 29: 957–962
Oxford Centre for Evidence based Medicine (2001) Levels of Evidence. http://minerva.minervation.com/cebm/
Patterson H, Norman AR, Mitra SS et al. (2001) Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 59: 5–11
Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115: 822–827
Ray B, Hajdu SI, Whitmore WF (1974) Distribution of retroperitoneal lymph node metastases in germinal tumors. Cancer 33: 340–348
Schmidberger H, Bamberg M (1995) Therapieoptionen bei testikulären Seminomen in den frühen Stadien. Strahlenther Onkol 171: 125–139
Schmidberger H, Bamberg M, Meisner C et al. (1997) Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiol Oncol Biol Phys 39: 321–326
Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v140–146
Scottish Intercollegiate Guidelines Network –SIGN (2011) Management of adult testicular germ cell tumours. A national clinical guideline 124. [http://www.sign.ac.uk/pdf/sign124.pdf]
Smalley SR, Evans RG (1996) Seminoma: management of stage II disease, posttherapy residual masses, and other special considerations. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds.) Comprehensive Textbook of Genitourinary Oncology.Williams u. Wilkins, Baltimore, pp 1038–1049
Sobin LH, Gospodarowicz MK, Wittekind Ch (eds) (2009) TNM classification of malignant tumours, 7th edn. John Wiley & Sons, New York
Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, Horwich A, Huddart R (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64: 362–367
Souchon R, Krege S, Schmoll HJ et al. für die German Testicular Cancer Study Group (GTCSG) (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Strahlenther Onkol 176: 388–405
Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R (2011) Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 187: 158–166
Spermon JR, De Geus-Oei LF, Kiemeney LA et al. (2002) The role of (18)fluoro–2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. Brit J Urol Int 89: 549–556
Thomas GM, Williams SD (1998) Testis. In: Perez CA, Brady LW (eds) Principles and Practice of Radiation Oncology. Lippincott-Raven Publisher, Philadelphia, pp 1695–1715
Travis LB, Fosså SD, Schonfeld SJ et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365
Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fosså SD (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102: 1114–1130
TRISST (MRC TE24) Trial of imaging and schedule in seminoma testis. [http://www.ctu.mrc.ac.uk/svtudies/TE24.asp]
UICC (International Union Against Cancer) (2006) Prognostic factors. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Cancer. 3rd ed. Lavoisier
Vallis KA, Howard GC, Duncan W, Cornbleet MA, Kerr GR (1995) Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. Br J Radiol 68: 400–405
van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA (2008) Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 98: 1894–1902
van den Belt-Dusebout AW, de Wit R, Gietema JA et al. (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370–4378
Vallis KA, Howard GC, Duncan W, Cornbleet MA, Kerr GR (1995) Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. Br J Radiol 68: 400–405
von der Maase H (2001) Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB? Radiother Oncol 59: 1–3
Warde P, Gospodarowicz M, Panzarella T et al. (1998) Management of stage II seminoma. J Clin Oncol 16: 290–294
Weissbach L, Boedefeld EA (1987) Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138: 77–82
Weissbach L, Bussar-Maatz R, Löhrs U et al. (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36: 601–608
Whipple GL, Sagerman RH, van Rooy EM (1997) Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. Am J Clin Oncol 20: 196–201
White PM, Howard GC, Best JJ, Wright AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 52: 124–129
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P (2010) Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4: e19–38
Yao WQ, Fosså SD, Dearnaley D, Horwich A (1994) Combined single course carboplatin with radiotherapy in treatment of Stage IIA, B seminoma – a preliminary report. Radiother Oncol 33: 88–90
Zagars GK, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51: 643–649
Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647
Literatur zu ▶ Abschn. 25.10
Albers P, Albers J, Cummings OW, Boris M, Donohue JP, Foster RS (1995) Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy [letter]. Eur J Cancer 31A (5): 848–849
Beck SD, Cheng L, Bihrle R, Donohue JP, Foster RS (2007) Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvante chemotherapy? J Urol 177: 944–6
De Wit M, Hartmann M, Kotzerke J, Wirth M, Brenner W, Hellwig D, Lehmann J, Heicappell R, Bokemeyer C, Bares R (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol 23:4504 (Supplement)
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A (10): 1599–1604
Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10 (1): 277–284
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin. 55:10–30
Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, Bosl GJ, Motzer RJ (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Journal of Clinical Oncology 22:464–467
Richie JP, Kantoff PW (1991): Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 9 (8): 1393–1396
Schmoll HJ, Souchon R, Krege S et al. and the European Germ Cell Cancer Consensus Group (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377–1399
Sesterhenn IA, Weiss RB, Mostofi FK et al. (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10 (1): 69–78
Sheinfeld J, Motzer RJ, Rabbani F, McKiernan J, Bajorin D, Bosl GJ (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and II A nonseminomatous germ cel tumors. Journal of Urology 170: 1159–62
Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT (1999) The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int. 84:68–74
Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G, Hobisch A (2004) Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology. 63:550–555
Steiner H, Muller T, Gozzi C, Akkad T, Bartsch G, Berger AP (2006) Related Articles, Links. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int 98 (2): 349–352 (Epub 2006 Apr 18)
Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788
Weissbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146 (5): 1295–1298
Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37 (5): 582–594
Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317 (23): 1433–1438
Literatur zu ▶ Abschn. 25.11
International Germ Cell Consensus Classification (1997) a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603
Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Kuczyk M, Fimmers R (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171: 1835–1838
Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Flechon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M (2012) 2-18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23: 59–64
Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606
Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153: 976–980
Besse B, Flechon A, Caty A, Chevreau C, Culine S, Grunenwald D, Fizazi K (2005) No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors. Proc Am Soc Clin Oncol 24 (abstr. 4524)
Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400–407
Bokemeyer C, Droz JP, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 91: 1394–1401
Bokemeyer C, Kohrmann O, Tischler J, Weissbach L, Rath U, Haupt A, Schoffski P, Harstrick A, Schmoll HJ (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 7: 1015–1021
Bokemeyer C, Kollmannsberger C, Flechon S, Stenning S, Droz JP, Horwich A, Clemm C, Fosså SD, Hartmann JT, Rueckerl C-P, Kanz L (2002) Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. Proc Am Soc Clin Oncol 21: 186a (abstr. 740)
Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 17: 3450–3456
Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J, Kanz L (2002) Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87: 1066–1071
Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT (2003) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 89: 29–35
Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, Scher H, Vogelzang NJ, Auman J, Carey R (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231–1238
Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore WF, Jr., Vugrin D, Scher H, Nisselbaum J, Golbey RB (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407
Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crepel M, Cloutier V, Baillargeon-Gagne S, Shariat SF, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI (2009) Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology 74: 373–377
Christian JA, Huddart RA, Norman A, Mason M, Fosså S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 21: 871–877
Clemm C, Bokemeyer C, Gerl A, Holzel D, Weissbach L, Bamberg M, Schoffski P, Harstrick A, Schmoll HJ, Wilmanns W (2000) Randomized Trial Comparing Cisplatin/Etoposide/ Ifosfamide with Carboplatin Monochemotherapy in Patients with Advanced Metastatic Seminoma. Proc Am Soc Clin Oncol 19: 326a (abstr. 1283)
Clemm C, Gerl A, Hentrich M (1995) Chemotherapy for far advanced seminoma. Onkologie 18: 189 (abstr. 909)
Collette L, Sylvester RJ, Stenning SP, Fosså SD, Mead GM, De Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye SB (1999) Impact of the treating institution on survival of patients with “poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91: 839–846
Collins Dh, Pugh RC (1964) classification and frequency of testicular tumours. Br J Urol 36: Suppl 11
Coogan CL, Hejase MJ, Wahle GR, Foster RS, Rowland RG, Bihrle R, Donohue JP (1996) Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156: 1656–1658
Culine S, Kerbrat P, Kramar A, Theodore C, Chevreau C, Geoffrois L, Bui NB, Peny J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18: 917–924
Culine S, Kramar A, Theodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Heron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP (20008) Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26: 421–427
Djaladat H, Nichols C, Daneshmand S (2012) Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection. Ann Surg Oncol Epub ahead of print
Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ (2011). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).Ann Oncol 22(5): 1054–61.
De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J (2001) Predictive impact of 2–18fluoro–2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740–3744
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J (2004) 2-18 fluoro-deoxy-D-glucose positron.emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective mutlicentric SEMPET trial. J Clin Oncol 22: 1034–1039
De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629–1640
de Wit R, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L (2012) Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 10;30(8):792–9
De Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, Bokkel Huinink WW, Rea LA, Collette L, Sylvester R (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843
De Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314
De Wit R, Stoter G, Sleijfer DT, Neijt JP, Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78: 828–832
Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS, Bosl GJ (2003) Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21: 4285–4291
Donohue JP, Fox EP, Williams SD, Loehrer PJ, Ulbright TM, Einhorn LH, Weathers TD (1994) Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 12: 190–195
Droz JP, Culine S, Bouzy J, Theodore C, Geoffrois L, Biron P, Bui BN, Peny J, Kerbrat P, Chevreau C, Delva R, Fargeot P, Platini C, Fizazi K, Caty A, Kramar A (2001) Preliminary Results of a Randomized Trial Comparing Bleomycin, Etoposide, Cisplatin (BEP) and Cyclophosphamide, Doxorubicin, Cisplatin/Vinblastin, Bleomycin (CISCA/VB) for Patients (Pts) with Intermediate- and Poor-Risk Metastatic Non Seminomatous Germ-Cell Tumors (NSGCT). Proc Am Soc Clin Oncol 20: 173a (abstr. 690)
Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH (2010) Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28: 531–536
Einhorn LH, Williams SD, Mandelbaum I, Donohue JP (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48: 904–908
Ellison MF, Mostofi FK, Flanigan RC (1988) Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 140: 618–620
Feuer EJ, Sheinfeld J, Bosl GJ (1999) Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91: 816–818
Fizazi K, Culine S, Chen I (2004) Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol 15: 1295
Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M, Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fosså SD, Fromont G (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 19(2): 259–64
Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ (2002) Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86: 1555–1560
Fizazi K, Tjulandin S, Salvioni R, Germa-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol 19: 2647–2657
Fosså SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O (1987) The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 5: 1071–1077
Fosså SD, Droz JP, Stoter G, Kaye SB, Vermeylen K, Sylvester R (1995) Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 71: 619–624
Fosså SD, Ous S, Lien HH, Stenwig AE (1989) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141: 557–559
Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, Einhorn LH (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294–1299
Friedman NB (1987) The function of the primordial germ cell in extragonadal tissues. Int J Androl 10: 43–49
Ganjoo KN, Chan RJ, Sharma M, Einhorn LH (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17: 3457–3460
Gels ME, Nijboer AP, Hoekstra HJ, Sleijfer DT, Molenaar WM, Plukker JT, Droste JH, Schraffordt KH (1997) Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol 79: 263–268
Gerl A, Clemm C, Schmeller N, Dienemann H, Lamerz R, Kriegmair M, Wilmanns W (1995) Outcome analysis after post-chemotherapy surgery in patients with non- seminomatous germ cell tumours. Ann Oncol 6: 483–488
Gerl A, Clemm C, Schmeller N, Dienemann H, Weiss M, Kriegmair M, Lohrs U, Wilmanns W (1994) Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 70: 960–965
Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C (2003) Advanced seminoma–treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 98: 745–752
Gregory C, Peckham MJ (1986) Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 6: 285–292
Hahn TL, Jacobson L, Einhorn LH, Foster R, Goulet RJ, Jr. (1999) Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 6: 640–644
Hartmann JT, Bamberg M, Albers M, Clemm C, Souchon R, Oechsle K, Weissbach L, Kanz L, Bokemeyer C (2003) Multidisciplinary treatment and prognosis of patients (pts) with central nervous system metastases (CNS) from testicular germ cell tumor (GCT) origin. Proc Am Soc Clin Oncol 22: 400 (abstr. 1607)
Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C (2001) Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 19: 1641–1648
Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Einhorn L, Kanz L, Bokemeyer C (2000) The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 88: 2629–2635
Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Fizazi K, Einhorn L, Kanz L, Bokemeyer C (2000) Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 92: 54–61
Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fosså SD, Beyer J, Pont J, Kanz L, Einhorn L, Bokemeyer C (2002) Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13: 1017–1028
Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schoffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C (2005) Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg 242: 260–266
Hartmann JT, Schleucher N, Metzner B, Kohne CH, Gerl A, Schleicher J, Rick O, Derigs HG, Beyer J, Boehlke I, Kanz L, Bokemeyer C (2001) Phase I/II study of sequential high dose VIP plus paclitaxel supported by PBSC in patients with ‚poor prognosis‘ germ cell tumor (GCT). Proc Am Soc Clin Oncol 20: 173a (abstr. 691)
Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C (2007) Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 25: 5742–5747
Hartmann JT, Classen J, Bokemeyer C (2003) Chemotherapie bei Keimzelltumoren mit intermediärer und schlechter Prognose. Onkologie 9: 985–991
Heidenreich A, Ohlmann C, Hegele A, Beyer J (2005) Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 47: 64–71
Hendry WF, A‘Hern RP, Hetherington JW, Peckham MJ, Dearnaley DP, Horwich A (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non- seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 71: 208–213
Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94: 1668–1678
Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157: 860–862
Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David CE, Vogelzang N, Trump D, Loehrer PJ Sr. (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97: 1869–1875
Horwich A, Dearnaley DP, A’Hern R, Mason M, Thomas G, Jay G, Nicholls J (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310
Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, Roberts JT, Fosså SD, Dearnaley DP, Lallemand E, Stenning SP (2000) A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 83: 1623–1629
Horwich A, Paluchowska B, Norman A, Huddart R, Nicholls J, Fisher C, Husband J, Dearnaley DP (1997) Residual mass following chemotherapy of seminoma. Ann Oncol 8: 37–40
Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, De Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852
Jones DM, Amato RJ, Pagliaro LC, Millikan R, Ellerhorst J, Tu SM, Logothetis CJ (1997) Carboplatin (CBDCA) and cyclophosphamide (CTX) and delayed selective consolidation in advanced seminoma (Meeting abstract). Proc Am Soc Clin Oncol 16: 323a (abstr. 1149)
Kaye SB, Mead GM, Fosså S, Cullen M, deWit R, Bodrogi I, Van Groeningen C, Sylvester R, Collette L, Stenning S, de Prijck L, Lallemand E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692–701
Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, Hayes-Lattin B, Nichols C (2010) Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 28: 637–542
Kopp HG, Kuczyk M, Classen J, Stenzl A, Kanz L, Mayer F, Bamberg M, Hartmann JT (2006) Advances in the treatment of testicular cancer. Drugs 66 (5): 641–659
Loehrer PJ, Sr., Birch R, Williams SD, Greco FA, Einhorn LH (1987) Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5: 1212–1220
Loehrer PJ, Sr., Johnson D, Elson P, Einhorn LH, Trump D (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476
Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH (1998) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540–546
Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD (1987) Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol 138: 789–794
Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J (2012) Clinical impact of residual extraperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology 79: 156–159
Mead GM, Stenning SP (1997) The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 9: 207–209
Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12: 120–126
Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN, Jr., Einhorn L, Mazumdar M, Bosl GJ (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247–256
Mulders PF, Oosterhof GO, Boetes C, de Mulder PH, Theeuwes AG, Debruyne FM (1990) The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 66: 425–429
Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73: 2520–2526
Napier MP, Naraghi A, Christmas TJ, Rustin GJ (2000) Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours. Br J Cancer 83: 1274–1280
Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287–1293
Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322: 1425–1429
Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163–1172
Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, Kliesch S, Mueller S, Krege S, Heicappell R, Bares R, Bokemeyer C, de Wit M (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26: 5930–5935
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14: 91–96
Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040
Pizzocaro G, Salvioni R, Piva L, Zanoni F, Milani A, Faustini M (1986) Cisplatin combination chemotherapy in advanced seminoma. Cancer 58: 1625–1629
Rivoire M, Elias D, De Cian F, Kaemmerlen P, Theodore C, Droz JP (2001) Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 92: 578–587
Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16: 702–706
Schirren J, Trainer S, Eberlein M, Lorch A, Beyer J, Bölükbas S (2012) The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg Epub ahead to print
Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 72: 237–243
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld DK, Kanz L, Berdel WE, Andreesen R, Bokemeyer C (2003) Long-term results of first-line sequential high dose VIP chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase II study of the german testicular cancer study group. J Clin Oncol 23: 4083–4091
Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fosså SD, Skakkebaek NE, De Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz AL, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia dM, X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der MH, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399
Sleijfer S, Willemse PH, de Vries EG, van der Graaf WT, Schraffordt KH, Mulder NH (1996) Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Br J Cancer 74: 947–950
Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT (2001) Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91: 1304–1315
Steyerberg EW, Keizer HJ, Zwartendijk J, Van Rijk GL, Van Groeningen CJ, Habbema JD, Stoter G (1993) Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 68: 195–200
Steyerberg EW, Keizer HJ, Stoter G, Habbema JD (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 30A: 1231–1239
Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DT, Toner GC, Schraffordt KH, Mulders PF, Messemer JE, Ney K, Donohue JP (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–1187
Steyerberg EW, Gerl A, Fosså SD, Sleijfer DT, De Wit R, Kirkels WJ, Schmeller N, Clemm C, Habbema JD, Keizer HJ (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274
Tait D, Peckham MJ, Hendry WF, Goldstraw P (1984) Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50: 601–609
Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, Motzer RJ, Scher HI, Herr HW, Morse MJ (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694
Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357: 739–745
Willan BD, McGowan DG (1985) Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 11: 1769–1775
Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440
Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P (2012) Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Stud yGroup. Eur Urol 61: 403–409
Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman SJ, Stephens RL, Natale RB, Bouroncle BA, Blumenstein BA (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 9: 70–76
**ao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15: 2553–2558
Zon RT, Nichols C, Einhorn LH (1998) Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 16: 1294–1297
Literatur zu ▶ Abschn. 25.12
Albers P, Dommer K, Muller SC (1998) Hodentumoren. Todesfälle und Rezidive nach inadäquater Therapie. Urologe A 37: 625–628
Albers P, Ganz A, Hannig E et al. (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164: 381–384
André F, Fizazi K, Culine S, Droz JP, Taupin P, Lhommé C, Terrier-Lacombe MJ, Théodore C (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Europ J Cancer 36: 1389–1394
Beck SDW, Foster RS, Bihrle R, Einhorn LH, Donohue JP (2005) Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node Dissection. J Clin Oncol 23: 6149–6156
Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14: 2638–2645
Beyer J, Stenning S, Gerl A, Fosså S, Siegert W (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599–605
Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RSK, Bosl GJ (2003) Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21: 4285–4291
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357: 340–348
Farhat F, Culine S, Theodore C, Bekradda M, Terrier-Lacombe MJ, Droz JP (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193–1197
Fosså SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392–1399
Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367: 754–765
George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung S-H, Shen J, Finch DE, Kelley MR, Einhorn LH (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113–122
Hartmann J, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8: 531–538
Heidenreich A, Krege S, Flaßhove M (2004) Interdisziplinäre Kooperation in der Therapie von komplexen Patienten mit fortgeschrittenem testikulärem Keimzelltumor. Urol A 43:1521–1530
Heidenreich A, Ohlmann CH (2005) Metastasierte testikuläre Keimzelltumoren. Aktuelle Indikationen zur Residualtumorresektion nach induktiver Chemotherapie
Heidenreich A, Ohlmann CH, Hegele A, Beyer J (2005) Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 47: 64–71
Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94: 1668–1676
International Prognostic Factor Study Group (2010) Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. J Clin Oncol 28, 33: 4906–4911
Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marionv S, Sheinfeld J, Bosl GJ, Motzer RJ (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23: 6549–6555
Krege S, Beyer J, Souchon R, Albers P (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I + II. Eur Urol 53: 478–513
Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin C, Anastasias S, Machtens S, Merseburger A, Wegener G, Stenzel A, Hartmann JT, Jonas U (2004) Late relapse after treatment for nonseminomatous germ cell tumors according to a single center-based experience. World J Urol 22: 55–59
Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH, Berdel BE, Weissinger F, Schleicher J, Egerer G, Haas, A, Schirren R, Beyer J, Bokemeyer C, Rick O (2007) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25: 2778–2784
Lorch A, Neubauer A, Hackenthal et al. (2009) High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 21: 820–825
Lorch A, Bascoul-Mollevi, Kramar A et al. (2011) Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. J Clin Oncol 29, 16: 2178–2184
Lutke Holzik MF, Hoekstra HJ, Mulder NH, Suurmeijer AJH, Sleijfer DT, Gietema JA (2003) Non–germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol 10: 131–135
Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427–1431
Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173–1180
Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324–329
Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bouzy J, Droz JP, Biron P (2005) A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 16: 1152–1159
Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18: 1181–1186
Rick O, Bokemeyer C, Weinknecht S, Schirren J, Pottek T, Hartmann JT, Braun T, Rachud B, Weißbach L, Hartmann M, Siegert W, Beyer J (2004) Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22: 3713–3719
Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12: 1390–1393
Schmoll HJ, Beyer J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–185
Shahidi M, Norman A, Nicholls J, Dearnaley D, Horwich A, Huddart R (2002) Late recurrence in 1263 men with testicular germ cell tumours: Multivariate analysis of risk factors and implications for management. Cancer 95: 520–30
Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J (2008) Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 26: 5524–5529
Sonneveld DJ, Sleijfer DT, Koops HS, Keemers-Gels ME, Molenaar WM, Hoekstra HJ (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 82: 1343–1351
Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fosså SD, Horwich A, Jones WG, Newlands ES, Oliver RT, Stenwig AE, Wilkinson PM (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83: 1409–1419
Vaena DA, Abonour R, Einhorn LH (2003) Long-term survival after high-dose salvage-chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21: 4100–4104
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ (2002) Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 20: 297–301
Literatur zu ▶ Abschn. 25.13
Abouassaly R, Fosså SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN (2011) Sequelae of Treatment in Long-Term Survivors of Testis Cancer. Euro Urol 60: 516–526
Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Wessbach L, Loy V, Wittekind C, Hartmann M (2008) Randomized phase III trial comparing tetroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapie in the adjuvant treatment of stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18): 2966–2972
Albers P, Weinknecht S, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Fimmers R (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter study of the GTCSG. J Urol 171 (5): 1842–1843
Albers P, Albrecht W, Algaba F et al. (2011). EAU guidelines on testicular cancer: 2011 update. Eur Urol 60: 304–319
Bachner M, Loriot Y, Gross-Goupil M et al. (2012). 2–18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23(1): 50–64
Balint E, Lubau-Plozza B (1975) Fünf Minuten pro Patient. Suhrkamp Verlag
Bamberg, M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Schorscht J, Walter F, Engelhart-Cabillic R, Schulz D, Born H, Flink M (1999) Radiotherapy for stage I/IIA/IIB testicular seminoma. Int J Cancer 35: 293–298*
Baniel J Foster RS, Genin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of Testicular cancer. J Clin Oncol 13 (5): 1170–1176
Beyer J, Albers P, Altena R et al. (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ- cell cancer. Ann Oncol 24(4): 878–888
Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ (1997) Treatment of brain metastasis in patients with testicular cancer. J Clin Oncol 15: 1449–1454
Bosl GJ, Geller NL, Cirrincione C, Vogelsang NJ, Bosl GJ (1983) Multivariate analysis of Prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407
Bruns F, Bremer M, Meyer A, Karstens JH (2005) Adjuvant radiotherapy in stage I seminoma: Is there a role for further reduction of treatment volume? Acta Oncol 44. 142–148*
Buchholz TA, Walden TL, Prestidge BR (1998) Cost-effectivness of posttreatment survival after radiation therapy of early stage seminoma. Cancer 82 (6): 1126–1133*
Buchler T, Kubankova P, Boublikova L et al. (2011). Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 117(18): 4212–4218
Büttner R (2006) Psychotherapeutische Begleitung von Hodenkrebspatienten. Dyn Psychatrie, Heft 214/215
Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, Sheinfeld J (2006) Predicting teratoma in the retroperitoneum in men undergoing postchemotherapy retroperitoneal lymph node dissection. J Urol 176: 100–103
Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S (2011) Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients. Onkologie 34: 59–64
Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann U, Bamberger M (2003) Radiotherapy for stage IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6): 1101–1106
Classen J, Souchon R, Hehr T, Hartmann M, Hartmann JT, Bamberg M (2010). Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis. J Cancer Res Clin Oncol 136(2): 227–232
Claßen J, Souchon R, Schmidberger H, Spillner P, Hehr P, Bamberg M (2005) Ist Nachsorge (FU) nach adjuvanter Radiotherapie beim Seminom notwendig? Ergebnisse einer prospektiven Untersuchung an 675 Patienten. Strahlenther Oncol 181 (Suppl. 1): 61
Clemm C, Bokemeyer C (1998) Therapie des fortgeschrittenen Seminoms. Onkologie 4: 524–531
Cost NG, Adibi M, Lubahn JD, Romman A, Raj GV, Sagalowski AI, Margulis V (2012). Effect of testicular germ cell tumor therapy on renal function. Urology 80(3): 641–648
De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatnment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6): 1629–1640
Deutsche Krebsgesellschaft (2002) Leitlinie zur Diagnostk und Therapie vonHodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). Hrsg R Souchon, H-J Schmoll, S Krege für die German Testicular Cancer Study Group im Auftrag der Deutschen Krebsgesellschaft, 1. Aufl. Zuckschwerdt, München Bern Wien New York*
Dieckmann KP, Albers P, Classen J, de Witt M, Pichlmeier U, Rick O, Müllerleile U, Kuczyk M (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173: 824–829
Donohue JP, Thornhill JA, Forster RS, Bihrle R, Rowland R, Einhorn LA, Richie JP (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989). J Urol 153 (1): 85–89*
Flechon A, Culine S, Theodore C, Droz J-P (2005) Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol 48: 957–964
Fosså SD (2004). Long-term sequelae after cancer therapy. Acta Oncol 43 (2): 134–141
Fosså SD, Stenning SP, Gerl A, Horwich A, Cark PI, Wilkonson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999a) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumors. Br J Cancer 80(9): 1392–1399*
Gerl A, Barba M, Weiss M, Liedl B, Zimmermann F, Clemm C (2003). Hodentumoren. Manual Urogenitale Tumoren. Tumorzentrum München & Zuckschwerdt, München
Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Willmanns W (1995) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032*
Gietema JA, Meinardi T, Sleijfer DT, Hoekstra HJ, van der Graaf WTA (2002) Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapie for disseminated nonseminomatous testicular cancer. Ann Oncol 13: 1616–1620
Gilligan T (2011). Testicular cancer survivorship. Haematol Oncol Clin N Am 25: 627–639
Hartmann M, Büttner H, Dettmann R, Pottek T (1995) Atypische Metastasierungen von Keimzellzumoren. In: Schnorr D, Loening SA, Weißbach L (Hrsg) Hodentumoren. Testis Cancer. Blackwell, Berlin: 7–27
Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R (2011) Nachsorge von Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. Urologe 50: 830–835
Harvey ML, Geldart TR, Duell R, Mead GM, Tung K (2002) Routine computerised tomo- graphic scans of the thorax in surveillance in stage I testicular non-seminomatous germ- cell cancer – a necessary risk? Ann Oncol 13: 237–242*
Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD (2012). Long-term and late effects of germ cell testicular cancer treatment and implications for follw-up. J Clin Oncol 30: 3752–3763
Horwich A, Norman A, Fisher C, Hendry WF, Nichols J, Dearneley DP (1994) Primary chemotherapie for stage II nonseminomatous germ cell tumors of the testis. J Urol 151: 72–78*
International Germ Cell Cancer Collaborative Group (1997). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2): 106–130
Jewett MAS, Grabowski A, McKiernan J (2003) Managment of recurrence and follow-up for cancer. Urol Clin N Am 30: 819–830
Jones WG, Fosså SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005) Randomized trial of 30 versus 20 gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council trial TE18, European Organisation for the Research and Treatment of Cancer trial 30942 (ISRCTN18525328). J Clin Oncol 23 (6)1200–1209*
Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21(6): 1296–1301
Kondagunta GV, Motzer RJ (2006) Chemotherapy for advanced germ cell tumors. J Clin Oncol 24: 5493–5502
Krege S, Beyer J, Souchon R, Albers P, Albrecht E et al. (2008) European Consensus Conference on diagnosis and treatment of germ cell cancer: a report oft he second meeting oft the European Germ Cell Cancer Consensus Group (EGCCCG). Part I and II. Eur Urol 53: 478–513
Laguna MP, Klepp O, Horwich A, Algaba F, Bokemeyer C, Pizzokaro G, Cohn-Cedemark G, Albers P (2004) Guidelines on testicular cancer. Update March 2004. European Association of Urology
Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G (2003) Short course para-aortic radiation for stage I seminoma of the testis. Int J Rad Oncol Biol Phys 57 (5): 1304–1309*
Martin JM, Panzarelli T, Zwahlen DR, Chung P, Warde P (2007) Evidence-based guidelines for following stage I seminoma. Cancer 109: 2248–2256
Mead GM, Fosså SD, Oliver RT, Fogarty J, Pollock P, Stenning SP (2008) Relapse patterns in 2’466 stage I seminoma patients entered into Medical Research Council randomized trials. J Clin Oncol 26(suppl): abstr 5020
Mettler FA, Walter H, Terry T, Mahadevappa M (2008) n Effective Doses in Radiology and Diagnostic Nuclear Medicine: A Catalog. Radiology 248: 254–263
Mezvrishvili Z, Tchanturaia Z, Toidze T, Turmanidze N, Kekelidze M, Managadze L (2007) Is ultrasound of the retroperitoneum a valuable staging method in selecting testicular cancer patients for primary lymph node dissection? Urol Int 78: 226–229
Nord C, Bjoro T, Ellingsen D et al. (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44: 322–328
Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecher F (2012). Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 138(6): 947–952
Oldenburg J, Martin J, Fosså SD (2006) Late relapse of germ cell malignancies: incidence, management and prognosis. J Clin Oncol 24: 5508–5511
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Srenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC3098 study (ISRCTN27163214). J Clin Oncol 29(8): 957–962
Oliver RTD, Edmonds PM, Ong JYH, Ostrowski M, Jackson AW, Baille-Johnson H, Williams MV, Wiltshire CR, Mott T, Pratt WR, Trask CLW, Hope-Stone HF (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?Int J Rad Oncol Biol Phys 29 (1): 3–8*
Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay MJ, Robinson A, Neal DE, Williams M (2004). Long-term follow-up of anglian germ cell cancer proup: surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology 63(3): 556–561
Pottek TS, Diekmann KP (2005a) Nachsorge beim Hodentumor lohnt sich. Urologe 44: 1024–1030*
Pottek TS, Hartmann M, Bokemeyer C (2005b) Nachsorge und Spättoxizitäten bei Hodentu- moren. Dt Ärzteblatt 102 (48): 2642–2646
Richiardi L, Scelo G, Bofetta B et al. (2007) Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120: 623–631
Roeleveld TA, Horenblas S, Meinhardt W, van de Vijver M, Kooi M, ten Bokkel Huinink WW (2001) Surveillance can be the standard of care of stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166: 2166–2170*
Rustin GJ, Mead GM, Sally P, et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197- The National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 10: 1310–1315
Sandon I, Larsson US, Eriksson C (2000) An interview study of men discovering testicular patients with nonseminoma testis cancer. Cancer Nurs 23 (4): 304–309
Sogani PC, Perotti M, Herr HW, Fair WR, Thaler HT, Bosl G (1998) Clinical stage I testis Cancer: long-term outcome of patients on surveillance. J Urol 159 (3): 855–858*
Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R (2011) Interdisciplinary ecidence-based recommendations for the follow up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 187(3): 158–166
Spermon JR, Kiemeney LA, Meulemann EJ, Ramos L, Wetzels AM, Witjes JA (2003) Fertility in men with testicular germ cell tumors. Fertil Steril 79 (Suppl 3): 1543–1549
Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J (2005) Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcino- ma predominance and/or lymphovascular invasion. J Urol 174: 557–560*
Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stiener U, Sollberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrom H, Klepp O (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell cancer: the SWENOTECA management program. J Clin Oncol 27: 2122–2128
Tarin TV, Sonn G, Shingal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerrized tomography. J Urol 181(2): 627–632
Taylor MB, Carrington BM, Livsey JE, Logue JP (2001) The effect of radiotherapie treatment changes on sites of relapse in stage I testicular seminoma. Clin Radiol 56: 116–119*
Travis BL, Beard C, Allan JM, Dahl AA, Feldmann DR, Oldenburg J et al. (2010) Testicular Cancer Survivorship: Research an Recommendations. J Natl Cancer Inst 102(15): 1114–1130
Travis L, Anderson M, Holowaty E, Van Leeuwen F, Bergfeldt K, Lynch C, Kohler B, Wiklund R, Curtis H, Storm H, Clarke E, Hail P, Pukkala E, Sturgeon J, Boice J Jr., Gospodarowicz M, Stovall M, Gilbert E (1999) Risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Proc ASCO 18: 308a, Abstract 1185
Travis LB, Fosså SD, Schonfeld SJ McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson A, Kaijser M, Gospodarowicz M, Joensuu T, cohen RJ, Boice JD Jr, Dores GM, Gilbert ES (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Inst 97(18): 1354–1365
Trigo JM, Tabernero IM, Paz-Ares J, Garcia-Liano IL, Mora J, Lianes P, Esteban E, Salvador R, Lopez-Lopez JJ, Corte-Funes H (2001) Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 88: 162–168
TRISST(MRC TE24) trial of imaging and schedule in seminoma testis. www.ctu.mrc.ac.uk/studies/TE24.asp.
Vogelzang NJ, Torkelson JL, Kennedy BJ (1985) Hypomagnesiaemia, renal dysfunction and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56(12): 2765–2770
Warde P, Gospodarowicz MK, Bannerjee D et al. (1997) Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705–1710
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M von der Maase H (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20: 4448–4452
Weissbach L, Boedefeld EA, Horstmann-Dubral B (1990) Surgical treatment of stage I non- seminomatous germ cell testis tumor. Eur Urol 17: 97–106
Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Eur Urol 37: 582–594*
White PM, Howard GCW, Best JJK, Wriht AR (1997) The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumors. Clin Radiol 52: 124–129
Literatur zu ▶ Abschn. 25.14
Al-Agha OM, Axiotis CA (2007) An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 131: 311–317
Amin MB (2005) Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors. Mod Pathol 18 Suppl 2: S131–145
Bitker MO, Leo JP, Jardin A, Chatelain C (1986) Rare testicular tumors Apropos of 15 cases [in French]. Ann Urol (Paris) 20: 238–243
Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J Urol 150: 1509–10
Bonkat G, Ruszat R, Forster T, Wyler S, Dogra VS, Bachmann A (2007) Benign space-occupying cysts in the testis. An overview. [Article in German]. Urologe A 46: 1697–1703
Carmignani L, Colombo R, Gadda F, Galasso G, Lania A, Palou J, Algaba F, Villavicencio H, Colpi GM, Decobelli O, Salvioni R, Pizzocaro G, Rigatti P, Rocco F (2007) Conservative surgical therapy for leydig cell tumor. J Urol 178: 507–511
Cho JH, Chang JC, Park BH, Lee JG, Son CH (2002) Sonographic and MR imaging findings of testicular epidermoid cysts. AJR Am J Roentgenol 178: 743–748
Chomette G, Delcourt A, Auriol M (1985) Non germinal tumors of the testis. Prog Clin Biol Res 203: 35–45
Colecchia M, Nistal M, Gonzalez-Peramato P, Carmignani L, Salvioni R, Nicolai N, Regadera J (2007) Leydig cell tumor and hyperplasia: a review. Anal Quant Cytol Histol 29: 139–47
Conkey DS, Howard GC, Grigor KM, McLaren DB, Kerr GR (2005) Testicular sex cord-stromal tumours: the Edinburgh experience 1988–2002, and a review of the literature. Clin Oncol (R Coll Radiol) 17: 322–327
Dieckmann KP (1991) Pathogenese und Frühdiagnostik der germinalen Hodentumoren Habilitationsschrift. Freie Universität Berlin Fachbereich Medizin, Berlin
Dieckmann KP, Düe W, Loy V (1988) Intrascrotal metastasis of renal cell carcinoma Case report and review of the literature Eur Urol 15: 297–301
Dieckmann KP, Loy V (1993) Metachronous germ-cell and Leydig cell tumors of the testis Do testicular germ cell tumors and Leydig cell tumors share risk factors? Cancer 72: 1305–1307
Dieckmann KP, Loy V (1994a) Epidermoid cyst of the testis: A review of clinical and histogenetic considerations. Br J Urol 73: 436–441
Dieckmann KP, Loy V (1994b) Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy. J Urol 151: 1024–1026
Düe W, Dieckmann KP, Niedobitek G, Bornhöft G, Loy V, Stein H (1990) Testicular sex cord stromal tumour with granulosa cell differentiation: detection of steroid hormone receptors as a possible basis for tumour development and therapeutic management. J Clin Pathol 43: 732–737
Dutt N, Bates AW, Baithun SI (2000) Secondary neoplasms of the male genital tract with different patterns of involvement in adults and children Histopathology 37: 323–331
Eble JN, Sauter G, Epstein JI, Sesterhenn IAE (2004) World health Organization Classification of Tumours Pathology, Genetics Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon
Emerson RE, Ulbright TM (2007) Morphological approach to tumours of the testis and paratestis. J Clin Pathol 60: 866–880
Fischer D, Kurth KH, Löhr J (1975) Die Bedeutung der histologischen Diagnostik für die Behandlung der Hodentumoren. Z Urol Nephrol 67: 465–472
Giannarini G, Mogorovich A, Menchini Fabris F, Morelli G, De Maria M, Manassero F, Loggini B, **itore R, Cavazzana A, Selli C (2007) Long-term followup after elective testis sparing surgery for Leydig cell tumors: a single center experience. J Urol 178: 872–876
Gundrum JD, Mathiason MA, Moore DB, Go RS (2009) Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol 27: 5227–32
Hammerich KH, Hille S, Ayala GE, Wheeler TM, Engers R, Ackermann R, Mueller-Mattheis V (2008) Malignant advanced granulosa cell tumor of the adult testis: case report and review of the literature. Hum Pathol 39: 701–709
Harzmann R, Stiens R (1982) Intraskrotale nichtgerminale Tumoren In Register und Verbundstudie für Hodentumoren – Bonn. In: Weißbach L, Hildenbrand G (Hrsg) Zuckschwerdt, München, S 306–339
Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T (2004) Testicular lymphoma – a retrospective population-based clinical and immunohistochemical study. Acta Oncol 43: 758–765
Heidenreich A, Zumbe J, Vorreuther R, Klotz T, Vietsch H, Engelmann UH (1996) Testikuläre Epidermiszyste: Orchiektomie oder Enukleationsresektion? Urologe A 35: 1–5
Heidrich A, Bollmann R, Knipper A (1999) Hodenmetastase eines Prostatakarzinoms drei Jahre nach subkapsulärer Orchiektomie. Urologe A 38: 279–281
Hoepffner W, Horn LC, Simon E, Sauerbrei G, Schroder H, Thamm-Mucke B, Bennek J, Kiess W (2005) Gonadoblastomas in 5 patients with 46,XY gonadal dysgenesis. Exp Clin Endocrinol Diabetes 113: 231–235
Horne MJ, Adeniran AJ (2011) Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med 135: 1363–1367
Iczkowski KA, Bostwick DG, Roche PC, Cheville JC (1998) Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol 11: 774–779
Jorgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE (1997) Heterogeneity of gonadoblastoma germ cells: similarities with immature germ cells spermatogonia and testicular carcinoma in situ cells. Histopathology 30: 177–86
Kersemaekers AM, Honecker F, Stoop H, Cools M, Molier M, Wolffenbuttel K, Bokemeyer C, Li Y, Lau YF, Oosterhuis JW, Looijenga LH (2005) Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY. Hum Pathol 36: 512–521
Kim I, Young RH, Scully RE (1985) Leydig cell tumors of the testis A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 9: 177–192
Krag Jacobsen G, Talerman A (1989) Atlas of germ cell tumors. Munksgaard, Copenhagen
Lawrence WD, Young RH, Scully RE (1986) Sex cord - stromal tumors. In: Talerman A, Roth LM (eds) Pathology of the testis and its adnexa. Churchill Livingstone, New York, pp 67–92
Leonhartsberger N, Ramoner R, Aigner F, Stoehr B, Pichler R, Zangerl F, Fritzer A, Steiner H (2011) Increased incidence of Leydig cell tumours of the testis in the era of improved imaging techniques. BJU Int 108: 1603–1607
Liu ZW, Zhang XQ, Hou GL, Zhang ZL, Qin ZK, Han H, Zhou FJ (2011) Primary adult intratesticular rhabdomyosarcoma: results of the treatment of six cases. Int J Urol 18: 171–174
Loy V, Linke J (2003) Endokrine Tumoren des Hodens. Pathologe 24: 308–313
Manning MA, Woodward PJ (2010) Testicular epidermoid cysts: sonographic features with clinicopathologic correlation. J Ultrasound Med 29: 831–837
Masur Y, Steffens J, Ziegler M, Remberger K (1996) Leydigzell-Tumoren des Hodens – klinische und morphologische Aspekte. Urologe A 35: 468–471
Mikuz G, Colecchia M (2007) Tumors of the testis and paratesticular structures. In Clinical Pathology of Urologic Tumors., Mikuz G (ed), pp 161–214. London: Informa Healthcare
Mikuz G, Kiesler J, Scheiber K, Dietze O (1984) Morphology and incidence of testicular tumors in western Austria (1945–1980). Zentralbl Allg Pathol 129: 91–100
Mostofi FK, Price EB (1973) Tumors of the male genital system. Atlas of tumor pathology. Second series. Fascicle 8. Armed Forces Institute of Pathology: Washington
Musser JE, Ernest AJ, Thibault GP, McMann LP (2011) Primary adenocarcinoma of the rete testis: improved staging accuracy with CT-PET. Urology 77: 334
Petersen RO, Sesterhenn IA, Davis CJ (2008) Testis. In: Urologic pathology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 313–405
Pugh RCB (1976) Pathology of the testis. Blackwell, Oxford
Rathert M, Ubrig B, Atkins DJ, Roth S (2011) Insuläres Karzinoid des Hodens. [Carcinoid tumor of the testis.][Article in German]. Urologe A 50: 340–342
Schmorl P, Ostertag H, Conrad S (2008) Intratestikuläre Metastasierung eines Nierenzellkarzinoms. Urologe 47: 1001–1003
Schnell D, Thon WF, Stief CG, Heymer B, Altwein JE (1987) Organerhaltendes Vorgehen bei gutartigem Hodentumor? Aktuel Urol 18: 127–132
Scully RE (1970) Gonadoblastoma A review of 74 cases Cancer 25: 1340–1356
Slowikowska-Hilczer J, Romer TE, Kula K (2003) Neoplastic potential of germ cells in relation to disturbances of gonadal organogenesis and changes in karyotype. J Androl 24: 270–278
Stein K, Maruschke M, Domke R, Hakenberg OW (2011) [Testicular metastases from prostate cancer].[Article in German]. Urologe 50: 208–209
Stewart VR, Sidhu PS (2007) The testis: the unusual, the rare and the bizarre. Clin Radiol 62: 289–302
Stroosma OB, Delaere KP (2008) Carcinoid tumours of the testis. BJU Int 101: 1101–1105
Suardi N, Strada E, Colombo R, Freschi M, Salonia A, Lania C, Cestari A, Carmignani L, Guazzoni G, Rigatti P, Montorsi F (2009) Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience. BJU Int 103: 197–200
Teilum G (1976) Special tumors of ovary and testis and related extragonadal lesions., 2nd edn. Munksgaard: Copenhagen
Ulbright TM, Young RH (2008) Metastatic Carcinoma to the Testis: A Clinicopathologic Analysis of 26 Nonincidental Cases With Emphasis on Deceptive Features. Am J Surg Pathol 32: 1683–1693
Vahlensieck W Jr, Zemann W (1990) Nicht-germinale Hodentumoren bei Erwachsenen. Beitr Onkol 40: 9–26
Vitolo U, Ferreri AJ, Zucca E (2008) Primary testicular lymphoma. Crit Rev Oncol Hematol 65: 183–189
von Hochstetter AR, Hedinger CE (1982) The differential diagnosis of testicular germ cell tumors in theory and practice A critical analysis of two major systems of classifiction and review of 389 cases. Virchows Arch A Pathol Anat Histol 396: 247–277
Walz P (1997) Seltene intraskrotale Tumoren. Aktuel Urol 28: 65–75
Wang WP, Guo C, Berney DM, Ulbright TM, Hansel DE, Shen R, Ali T, Epstein JI (2010) Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol 34: 519–524
Weissbach L, Schaefer C (2008) Organerhaltende Hodentumorchirurgie. Urologe 47: 809–817
Wurster K (1976) Klassifizierung testikulärer Keimzellgeschwülste. Thieme, Stuttgart
Young RH (2008) Testicular tumors-some new and a few perennial problems. Arch Pathol Lab Med 132: 548–564
Young RH, Scully RE (1990) Testicular tumors. American Society of Clinical Pathologists Press: Chicago
Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thieblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, ltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, Group, IELS (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21: 20–27
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Albers, P. et al. (2014). Maligne Hodentumoren. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-35032-0_25
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35031-3
Online ISBN: 978-3-642-35032-0
eBook Packages: Medicine (German Language)